{"cached_at":"2026-10-20T10:43:08.408499+00:00","cl_docket_id":"70274365","docket":{"resource_uri":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","id":70274365,"court":"https://www.courtlistener.com/api/rest/v4/courts/cand/","court_id":"cand","original_court_info":null,"idb_data":null,"clusters":[],"audio_files":[],"assigned_to":null,"referred_to":"https://www.courtlistener.com/api/rest/v4/people/9087/","bankruptcy_information":null,"absolute_url":"/docket/70274365/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2025-05-15T12:35:43.779957-07:00","date_modified":"2026-10-15T06:59:54.218989-07:00","source":1,"appeal_from_str":"","assigned_to_str":"Eumi K. Lee","referred_to_str":"Nathanael M. Cousins","panel_str":"","date_last_index":null,"date_cert_granted":null,"date_cert_denied":null,"date_argued":null,"date_reargued":null,"date_reargument_denied":null,"date_filed":"2025-05-15","date_terminated":null,"date_last_filing":"2026-10-14","case_name_short":"","case_name":"In re Iovance Biotherapeutics, Inc. Securities Litigation","case_name_full":"","slug":"in-re-iovance-biotherapeutics-inc-securities-litigation","docket_number":"5:25-cv-04177","docket_number_core":"2504177","docket_number_raw":"5:25-cv-04177","docket_number_source":0,"federal_dn_office_code":"5","federal_dn_case_type":"cv","federal_dn_judge_initials_assigned":"EKL","federal_dn_judge_initials_referred":"","federal_defendant_number":null,"pacer_case_id":"449628","cause":"15:78m(a) Securities Exchange Act","nature_of_suit":"850 Securities/Commodities","jury_demand":"Plaintiff","jurisdiction_type":"Federal Question","appellate_fee_status":"","appellate_case_type_information":"","mdl_status":"","filepath_ia":"","filepath_ia_json":"","ia_upload_failure_count":null,"ia_needs_upload":true,"ia_date_first_change":"2025-05-15T12:35:43.764781-07:00","date_blocked":null,"blocked":false,"appeal_from":null,"parent_docket":null,"tags":[],"panel":[]},"parties":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203159/","id":17203159,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215662/","attorney_id":11215662,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Interested Party","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:46.774272-08:00","date_modified":"2026-01-27T00:03:46.774282-08:00","name":"Samhita Gera","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203158/","id":17203158,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/10548640/","attorney_id":10548640,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/10548640/","attorney_id":10548640,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":2},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215660/","attorney_id":11215660,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215660/","attorney_id":11215660,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215661/","attorney_id":11215661,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:46.004667-08:00","date_modified":"2026-01-27T00:03:46.004676-08:00","name":"Anthony Westfall","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203157/","id":17203157,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215657/","attorney_id":11215657,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215657/","attorney_id":11215657,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215658/","attorney_id":11215658,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215659/","attorney_id":11215659,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:45.597238-08:00","date_modified":"2026-01-27T00:03:45.597253-08:00","name":"Brian Paplaski","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203156/","id":17203156,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215654/","attorney_id":11215654,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215655/","attorney_id":11215655,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215656/","attorney_id":11215656,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:45.406583-08:00","date_modified":"2026-01-27T00:03:45.406592-08:00","name":"Mehdi Hasan","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203155/","id":17203155,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/10548630/","attorney_id":10548630,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215639/","attorney_id":11215639,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215640/","attorney_id":11215640,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:45.319051-08:00","date_modified":"2026-01-27T00:03:45.319060-08:00","name":"Hassan Pourhossein","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203154/","id":17203154,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/10548630/","attorney_id":10548630,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215639/","attorney_id":11215639,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215640/","attorney_id":11215640,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:45.235700-08:00","date_modified":"2026-01-27T00:03:45.235710-08:00","name":"JianJun Wei","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203153/","id":17203153,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215653/","attorney_id":11215653,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"Lee Schweizer, Michael A. Macchione, Ann Marie Macchione, Bradford J. Tierney, and Christopher J. Amoruso","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:44.999212-08:00","date_modified":"2026-01-27T00:03:44.999222-08:00","name":"The Iova Investor Group","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203152/","id":17203152,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215652/","attorney_id":11215652,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215652/","attorney_id":11215652,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":2}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:44.953218-08:00","date_modified":"2026-01-27T00:03:44.953227-08:00","name":"Elliot Resnick","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203151/","id":17203151,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215652/","attorney_id":11215652,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215652/","attorney_id":11215652,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":2}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:44.896571-08:00","date_modified":"2026-01-27T00:03:44.896581-08:00","name":"Thor Brevik","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203150/","id":17203150,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215649/","attorney_id":11215649,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215649/","attorney_id":11215649,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215649/","attorney_id":11215649,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":2},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215650/","attorney_id":11215650,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215651/","attorney_id":11215651,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215651/","attorney_id":11215651,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:44.813577-08:00","date_modified":"2026-01-27T00:03:44.813586-08:00","name":"Tony Djie","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203149/","id":17203149,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215649/","attorney_id":11215649,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215649/","attorney_id":11215649,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215649/","attorney_id":11215649,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":2},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215650/","attorney_id":11215650,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215651/","attorney_id":11215651,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215651/","attorney_id":11215651,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:44.644392-08:00","date_modified":"2026-01-27T00:03:44.644402-08:00","name":"Lindy Merrill","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203148/","id":17203148,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215646/","attorney_id":11215646,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215646/","attorney_id":11215646,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":2},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215647/","attorney_id":11215647,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215648/","attorney_id":11215648,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:44.383065-08:00","date_modified":"2026-01-27T00:03:44.383074-08:00","name":"Peter Jay Guthy","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203147/","id":17203147,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/10352631/","attorney_id":10352631,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/10352631/","attorney_id":10352631,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":2}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:44.338620-08:00","date_modified":"2026-01-27T00:03:44.338629-08:00","name":"Gary LoPiccolo","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203146/","id":17203146,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/10548634/","attorney_id":10548634,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/10548634/","attorney_id":10548634,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":2},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215645/","attorney_id":11215645,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:44.053071-08:00","date_modified":"2026-01-27T00:03:44.053080-08:00","name":"Mark van den Broek","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203145/","id":17203145,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215641/","attorney_id":11215641,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215641/","attorney_id":11215641,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215642/","attorney_id":11215642,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215642/","attorney_id":11215642,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215643/","attorney_id":11215643,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215644/","attorney_id":11215644,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215644/","attorney_id":11215644,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Defendant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:43.954583-08:00","date_modified":"2026-01-27T00:03:43.954592-08:00","name":"Daniel G. Kirby","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203144/","id":17203144,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215641/","attorney_id":11215641,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215641/","attorney_id":11215641,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215642/","attorney_id":11215642,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215642/","attorney_id":11215642,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215643/","attorney_id":11215643,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215644/","attorney_id":11215644,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215644/","attorney_id":11215644,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Defendant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:43.856780-08:00","date_modified":"2026-01-27T00:03:43.856789-08:00","name":"Igor P. Bilinsky","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203143/","id":17203143,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215641/","attorney_id":11215641,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215641/","attorney_id":11215641,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215642/","attorney_id":11215642,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215642/","attorney_id":11215642,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215643/","attorney_id":11215643,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215644/","attorney_id":11215644,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215644/","attorney_id":11215644,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Defendant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:43.757840-08:00","date_modified":"2026-01-27T00:03:43.757850-08:00","name":"Jean-Marc Bellemin","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203142/","id":17203142,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215641/","attorney_id":11215641,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215641/","attorney_id":11215641,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215642/","attorney_id":11215642,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215642/","attorney_id":11215642,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215643/","attorney_id":11215643,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215644/","attorney_id":11215644,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215644/","attorney_id":11215644,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Defendant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:43.661382-08:00","date_modified":"2026-01-27T00:03:43.661391-08:00","name":"Frederick G. Vogt","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203141/","id":17203141,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215641/","attorney_id":11215641,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215641/","attorney_id":11215641,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215642/","attorney_id":11215642,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215642/","attorney_id":11215642,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215643/","attorney_id":11215643,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215644/","attorney_id":11215644,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":4},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215644/","attorney_id":11215644,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Defendant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:43.457488-08:00","date_modified":"2026-01-27T00:03:43.457505-08:00","name":"Iovance Biotherapeutics, Inc.","extra_info":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/parties/17203140/","id":17203140,"attorneys":[{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/10548630/","attorney_id":10548630,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215639/","attorney_id":11215639,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1},{"attorney":"https://www.courtlistener.com/api/rest/v4/attorneys/11215640/","attorney_id":11215640,"date_action":null,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"role":1}],"party_types":[{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Consol Plaintiff","date_terminated":null,"extra_info":"Individually and on Behalf of All Others Similarly Situated","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]},{"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","docket_id":70274365,"name":"Movant","date_terminated":null,"extra_info":"","highest_offense_level_opening":"","highest_offense_level_terminated":"","criminal_counts":[],"criminal_complaints":[]}],"date_created":"2026-01-27T00:03:42.857189-08:00","date_modified":"2026-01-27T00:03:42.857200-08:00","name":"Dimitry Farberov","extra_info":""}],"entries":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/481564277/","id":481564277,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/497310740/","id":497310740,"tags":[],"absolute_url":"/docket/70274365/107/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-10-14T16:04:40.097964-07:00","date_modified":"2026-10-14T16:04:40.108490-07:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"107","attachment_number":null,"pacer_doc_id":"035027791365","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Reply to Opposition/Response","acms_document_guid":""}],"date_created":"2026-10-14T16:04:40.058259-07:00","date_modified":"2026-10-15T06:59:54.740757-07:00","date_filed":"2026-10-14","time_filed":"15:46:20","entry_number":107,"recap_sequence_number":"2026-10-14.001","pacer_sequence_number":445,"description":"REPLY (re 103 MOTION to Dismiss Consolidated Amended Complaint for Violations of The Federal Securities Laws ) filed byJean-Marc Bellemin, Igor P. Bilinsky, Iovance Biotherapeutics, Inc., Frederick G. Vogt, James Zeigler. (Callahan, Veronica) (Filed on 10/14/2026) (Entered: 10/14/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/477963631/","id":477963631,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/493576432/","id":493576432,"tags":[],"absolute_url":"/docket/70274365/106/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-09-14T18:34:45.147063-07:00","date_modified":"2026-09-14T18:34:45.156911-07:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"106","attachment_number":null,"pacer_doc_id":"035027646710","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Opposition/Response to Motion","acms_document_guid":""}],"date_created":"2026-09-14T18:34:45.126254-07:00","date_modified":"2026-10-15T06:59:54.724937-07:00","date_filed":"2026-09-14","time_filed":"18:22:31","entry_number":106,"recap_sequence_number":"2026-09-14.001","pacer_sequence_number":442,"description":"OPPOSITION/RESPONSE (re 103 MOTION to Dismiss Consolidated Amended Complaint for Violations of The Federal Securities Laws ) filed byTony Djie, Lindy Merrill. (Attachments: # 1 Appendix A)(Fuks, Sara) (Filed on 9/14/2026) (Entered: 09/14/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/472865460/","id":472865460,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/488311778/","id":488311778,"tags":[],"absolute_url":"/docket/70274365/105/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-07-31T13:04:08.284091-07:00","date_modified":"2026-07-31T13:04:08.297557-07:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"105","attachment_number":null,"pacer_doc_id":"035027453568","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Order AND Set Motion and Deadlines/Hearings AND ~Util - Terminate Motions","acms_document_guid":""}],"date_created":"2026-07-31T13:04:08.252149-07:00","date_modified":"2026-10-15T06:59:54.705099-07:00","date_filed":"2026-07-31","time_filed":"12:51:12","entry_number":105,"recap_sequence_number":"2026-07-31.001","pacer_sequence_number":434,"description":"ORDER Granting AS MODIFIED 104 Joint Stipulation Re Plaintiffs' Opposition to Defendants' Motion to Dismiss and Defendants' Reply. Signed by Judge Eumi K. Lee on 7/31/2026. (lrt, COURT STAFF) (Filed on 7/31/2026) (Entered: 07/31/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/470096009/","id":470096009,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/485457106/","id":485457106,"tags":[],"absolute_url":"","date_created":"2026-07-08T09:33:04.213234-07:00","date_modified":"2026-07-08T09:33:04.219608-07:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"","attachment_number":null,"pacer_doc_id":"","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Set Motion and Deadlines/Hearings","acms_document_guid":""}],"date_created":"2026-07-08T09:33:04.199164-07:00","date_modified":"2026-07-08T09:33:04.199178-07:00","date_filed":"2026-07-08","time_filed":"09:22:15","entry_number":null,"recap_sequence_number":"2026-07-08.001","pacer_sequence_number":null,"description":"","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/467506430/","id":467506430,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482771999/","id":482771999,"tags":[],"absolute_url":"/docket/70274365/103/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T13:32:52.449716-07:00","date_modified":"2026-06-15T13:32:52.460019-07:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":null,"pacer_doc_id":"035027255223","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Dismiss","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798472/","id":482798472,"tags":[],"absolute_url":"/docket/70274365/103/1/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:00.443622-07:00","date_modified":"2026-06-15T15:39:00.443647-07:00","sha1":"","page_count":12,"file_size":207586,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":1,"pacer_doc_id":"035027255224","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Appendix","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798474/","id":482798474,"tags":[],"absolute_url":"/docket/70274365/103/2/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:00.561332-07:00","date_modified":"2026-06-15T15:39:00.561357-07:00","sha1":"","page_count":4,"file_size":163828,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":2,"pacer_doc_id":"035027255225","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Declaration of Veronica Callahan","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798476/","id":482798476,"tags":[],"absolute_url":"/docket/70274365/103/3/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:00.590651-07:00","date_modified":"2026-06-15T15:39:00.590673-07:00","sha1":"","page_count":10,"file_size":264681,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":3,"pacer_doc_id":"035027255226","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 1 - 2023.11.07  8-K, Ex.99.1","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798477/","id":482798477,"tags":[],"absolute_url":"/docket/70274365/103/4/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:00.635660-07:00","date_modified":"2026-06-15T15:39:00.635677-07:00","sha1":"","page_count":19,"file_size":436309,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":4,"pacer_doc_id":"035027255227","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 2 - 2023.11.07  Q3 2023 Earnings Call","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798491/","id":482798491,"tags":[],"absolute_url":"/docket/70274365/103/5/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:02.231625-07:00","date_modified":"2026-06-15T15:39:02.231646-07:00","sha1":"","page_count":58,"file_size":513473,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":5,"pacer_doc_id":"035027255228","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 3 - 2023.11.07  10-Q Q3 2023","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798497/","id":482798497,"tags":[],"absolute_url":"/docket/70274365/103/6/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:02.789169-07:00","date_modified":"2026-06-15T15:39:02.789190-07:00","sha1":"","page_count":16,"file_size":218364,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":6,"pacer_doc_id":"035027255229","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 4 - 2024.02.16  Investor Call","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798501/","id":482798501,"tags":[],"absolute_url":"/docket/70274365/103/7/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:03.183114-07:00","date_modified":"2026-06-18T05:08:00.253079-07:00","sha1":"0c64612ea8d936f0f7edb097061ac7cde5c635ce","page_count":9,"file_size":256049,"filepath_local":"recap/gov.uscourts.cand.449628/gov.uscourts.cand.449628.103.7.pdf","filepath_ia":"https://archive.org/download/gov.uscourts.cand.449628/gov.uscourts.cand.449628.103.7.pdf","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"Case 5:25-cv-04177-EKL   Document 103-7   Filed 06/15/26   Page 1 of 9\n\n\n\n\n               EXHIBIT 5\n\f            Case 5:25-cv-04177-EKL                            Document 103-7                Filed 06/15/26                Page 2 of 9\n\n\n\n\n                                                               UNITED STATES\n                                                   SECURITIES AND EXCHANGE COMMISSION\n                                                            Washington, D.C. 20549\n\n                                                                     FORM 8-K\n                                                                    Current Report\n\n                                      Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934\n\n                                           Date of Report (date of earliest event reported): February 28, 2024\n\n                                            IOVANCE BIOTHERAPEUTICS, INC.\n                                                   (Exact Name of Registrant as Specified in Charter)\n\n                                                                        Delaware\n                                                                (State of Incorporation)\n\n                            001-36860                                                                      XX-XXXXXXX\n                       Commission File Number                                                   (I.R.S. Employer Identification No.)\n\n                    825 Industrial Road, 4th Floor\n                        San Carlos, California                                                                 94070\n                (Address of Principal Executive Offices)                                                     (Zip Code)\n\n                                                                   (650) 260-7120\n                                               (Registrant\u2019s Telephone Number, Including Area Code)\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the\nfollowing provisions:\n\n\u00a8 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).\n\n\u00a8 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).\n\n\u00a8 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).\n\n\u00a8 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933\n(\u00a7230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (\u00a7240.12b-2 of this chapter). Emerging growth company \u00a8\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with\nany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \u00a8\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n                     Title of each class                                Trading                         Name of each exchange on which\n                                                                       Symbol(s)                                  registered\n     Common stock, par value $0.000041666 per share                      IOVA                            The Nasdaq Stock Market LLC\n\f             Case 5:25-cv-04177-EKL                       Document 103-7                  Filed 06/15/26             Page 3 of 9\n\n\nItem 2.02.        Results of Operations and Financial Condition.\n\n         On February 28, 2024, Iovance Biotherapeutics, Inc. (the \u201cCompany\u201d) issued a press release announcing its financial results for the fourth\nquarter and fiscal year ended December 31, 2023 and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1.\n\n          The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be \u201cfiled\u201d for the\npurposes of Section 18 of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d), or otherwise subject to the liability of such\nsection, nor shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act of\n1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.\n\nItem 9.01.        Financial Statements and Exhibits.\n\n         (d) Exhibits.\n\n  Exhibit\n   No.                                                                      Description\n   99.1        Press Release of Iovance Biotherapeutics, Inc., dated February 28, 2024.\n   104         Cover Page Interactive Data File (embedded as Inline XBRL document)\n\f            Case 5:25-cv-04177-EKL                        Document 103-7                  Filed 06/15/26              Page 4 of 9\n\n\n                                                                   SIGNATURES\n\n         Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf\nby the undersigned hereunto duly authorized.\n\n                                                                          Iovance Biotherapeutics, Inc.\n\nDated: February 28, 2024                                                  By:    /s/ Frederick G. Vogt\n                                                                          Name: Frederick G. Vogt, Ph.D.\n                                                                          Title: Interim CEO and General Counsel\n\f            Case 5:25-cv-04177-EKL                      Document 103-7                 Filed 06/15/26              Page 5 of 9\n\n\n                                                                                                                                  Exhibit 99.1\n\n                                      Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023\n                                                   Financial Results and Corporate Updates\n\n Amtagvi\u2122 (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-\n                                         Time, Individualized T cell Therapy for a Solid Tumor Cancer\n\n                         Amtagvi Regulatory Submissions on Track in the European Union, United Kingdom, and Canada\n\n Amtagvi Patients Identified at Nearly All of the 30 Authorized Treatment Centers (ATCs), with Approximately 50 ATCs Anticipated to be Ready\n                                                             by the End of May 2024\n\nSAN CARLOS, Calif., February 28, 2024 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on\ninnovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported\nfourth quarter and full year 2023 financial results and corporate updates.\n\nFrederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, \u201cThroughout 2023, we executed toward our first\napproval and commercial launch while advancing our pipeline. We are seeing healthy demand and momentum for Amtagvi\u2122 following the recent\nU.S. FDA approval in advanced melanoma. To expand the launch globally, we plan to submit regulatory dossiers in the European Union in the first\nhalf of 2024 and in Canada and the United Kingdom in the second half of 2024. We are also excited about our robust development pipeline across\nsolid tumor cancers. As a fully integrated company, Iovance is well positioned to execute on our regulatory, pipeline, manufacturing, and\ncommercial launch activities to advance our mission to remain the global leader in TIL therapy.\u201d\n\nRecent and Fourth Quarter 2023 Highlights and Corporate Updates\n\nAmtagvi\u2122 (lifileucel):\n\nU.S. Approval and Launch Highlights in Advanced Melanoma\n     \u00b7 The U.S. FDA approved Amtagvi on February 16, 2024, as the first treatment option for advanced melanoma after anti-PD-1 and targeted\n        therapy. Amtagvi is also the first FDA-approved T cell therapy for a solid tumor indication.\n     \u00b7 Onboarding is complete at approximately 30 U.S. authorized treatment centers (ATCs) and approximately 50 ATCs are expected to be\n        onboard by the end of May 2024.\n     \u00b7 The Iovance Cell Therapy Center (iCTC) began commercial manufacturing for Amtagvi patients within a week of approval. The iCTC, and\n        a nearby FDA-approved contract manufacturer, are built today for capacity for several thousands of patients annually.\n     \u00b7 The U.S. launch of Amtagvi, and additional sales of Proleukin\u00ae used with the treatment regimen, are expected to drive significant revenue\n        for Iovance in 2024.\n     \u00b7 Since approval, there are at least 20 Amtagvi patients in process, which includes 10 patients already registered in IovanceCaresT M with\n        scheduled or pending manufacturing slots.\n\f            Case 5:25-cv-04177-EKL                       Document 103-7                 Filed 06/15/26             Page 6 of 9\n\n\nLaunch Expansion into New Markets and Indications\n   \u00b7 Iovance\u2019s global expansion strategy can more than double the total addressable patient population for Amtagvi in advanced melanoma.\n       Anticipated regulatory submissions include the following:\n           o A marketing authorization application (MAA) in the European Union (EU) in the first half of 2024.\n           o An MAA in the U.K. and a new drug submission (NDS) in Canada in the second half of 2024.\n           o Regulatory submissions in Australia and additional countries with significant populations of advanced melanoma patients in\n                2025.\n   \u00b7 The registrational Phase 3 TILVANCE-301 trial is underway to support accelerated and full approvals of Amtagvi in combination with\n       pembrolizumab in frontline advanced melanoma.\n           o Global site activation and patient enrollment continue with strong momentum in the U.S., Europe, Australia, Canada, and\n                additional countries.\n           o Following the U.S. FDA\u2019s recent accelerated approval of Amtagvi in post-anti-PD-1 advanced melanoma, TILVANCE-301 is the\n                confirmatory trial to support full approval in this initial indication.\n           o An updated data cut for Cohort 1A of the IOV-COM-202 trial, in a presentation on the efficacy and safety of lifileucel and\n                pembrolizumab in patients with immune checkpoint inhibitor-naive advanced melanoma, is planned for a medical meeting this year\n                and is supportive of the rationale for TILVANCE-301.\n\nManufacturing Highlights\n   \u00b7 More than 700 patients have been treated with Iovance TIL therapy manufactured using proprietary Iovance processes as of December 31,\n       2023.\n   \u00b7 Capacity expansion is underway at iCTC to supply TIL cell therapies for more than 5,000 patients annually in the next few years.\n\nIovance TIL Therapy Clinical Pipeline Highlights\n    \u00b7 Enrollment in the registrational cohorts in the Phase 2 Trial IOV-LUN-202 in post-anti-PD-1 NSCLC is estimated to complete in 2025.\n        Iovance is working collaboratively with the U.S. FDA to resume new patient enrollment in IOV-LUN-202 following the partial clinical hold\n        for new patients on December 22, 2023.\n    \u00b7 A Phase 2 study in endometrial cancer in mismatch repair (MMR) deficient and MMR proficient patient populations is on track to\n        commence in the first half of 2024.\n    \u00b7 The first in human IOV-GM1-201 trial is investigating PD-1 inactivated TIL therapy (IOV-4001) in previously treated advanced melanoma\n        and NSCLC.\n\nCorporate Updates\n    \u00b7 As of February 22, 2024, Iovance\u2019s unaudited cash position is approximately $485.2 million, which includes net proceeds of approximately\n        $197.1 million from a follow-on equity financing in February of 2024. The current cash position and anticipated revenue from Amtagvi and\n        Proleukin are expected to be sufficient to fund current and planned operations well into the second half of 2025.\n    \u00b7 Iovance currently owns more than 60 granted or allowed U.S. and international patents for TIL compositions and methods of treatment and\n        manufacturing in a broad range of cancers, with Gen 2 patent rights expected to provide exclusivity into 2038 and additional patent rights\n        expected to provide exclusivity into 2042. More information on Iovance\u2019s patent portfolio is available on the Intellectual Property page\n        on www.iovance.com.\n\f            Case 5:25-cv-04177-EKL                         Document 103-7                  Filed 06/15/26              Page 7 of 9\n\n\nFourth Quarter and Full Year 2023 Financial Results\n\nIovance had $346.3 million in cash, cash equivalents, investments and restricted cash at December 31, 2023, compared to $478.3 million at December\n31, 2022. With the net proceeds of approximately $197.1 million raised in the February 2024 follow-on stock offering and anticipated revenue from\nAmtagvi and Proleukin, the cash position is expected to be sufficient to fund current and planned operations well into the second half of 2025.\n\nNet loss for the fourth quarter ended December 31, 2023, was $116.4 million, or $0.45 per share, compared to a net loss of $105.3 million, or $0.64 per\nshare, for the fourth quarter ended December 31, 2022. Net loss for the year ended December 31, 2023 was $444.0 million, or $1.89 per share,\ncompared to a net loss of $395.9 million, or $2.49 per share, for the year ended December 31, 2022. The net loss for the year ended December 31, 2023\nincludes amortization of intangible assets acquired as part of the Proleukin transaction.\n\nRevenue for the fourth quarter and year ended December 31, 2023, was $0.5 million and $1.2 million, respectively, and comprised of product sales\nfollowing the Proleukin\u00ae acquisition in May 2023. There was no revenue for the fourth quarter and year ended December 31, 2022. Cost of sales for\nthe fourth quarter and year ended December 31, 2023, was $4.4 million and $10.8 million, respectively, and comprised of cost of inventory associated\nwith sales of Proleukin\u00ae as well as $3.9 million and $9.7 million, respectively, of non-cash amortization expenses of the acquired intangible asset for\ndeveloped technology. There was no cost of revenues for the fourth quarter and year ended December 31, 2022.\n\nResearch and development expenses were $87.5 million for the fourth quarter ended December 31, 2023, an increase of $6.9 million compared\nto $80.6 million for the same period ended December 31, 2022. Research and development expenses were $344.1 million for the year ended December\n31, 2023, an increase of $49.3 million compared to $294.8 million for the same period ended December 31, 2022.\n\nThe increases in research and development expenses in the fourth quarter and the year ended December 31, 2023, over the prior year periods were\nprimarily attributable to increases in headcount and related costs to support internal manufacturing and clinical development activities,\nmanufacturing costs to support increased production and commercial manufacturing readiness, clinical trial costs driven primarily by the initiation\nof our Phase 3 TILVANCE-301 clinical trial, and facility and related costs to expand manufacturing capacity.\n\nSelling, general and administrative expenses were $29.9 million for the fourth quarter ended December 31, 2023, an increase of $3.4 million compared\nto $26.5 million for the same period ended December 31, 2022. Selling, general and administrative expenses were $106.9 million for the year ended\nDecember 31, 2023, an increase of $2.8 million compared to $104.1 million for the same period ended December 31, 2022.\n\nThe increase in selling, general and administrative expenses in the fourth quarter and the year ended December 31, 2023, compared to prior year\nperiods was primarily attributable to increases in headcount and related costs to support the growth in the overall business and related corporate\ninfrastructure, professional fees and travel costs, including costs associated with Proleukin\u00ae integration. These increases were partially offset by a\ndecrease in stock-based compensation expenses, legal and other costs. For additional information, please see the Company\u2019s Selected Condensed\nConsolidated Balance Sheet and Statement of Operations below.\n\f             Case 5:25-cv-04177-EKL                        Document 103-7                   Filed 06/15/26               Page 8 of 9\n\n\nWebcast and Conference Call\n\nTo participate in the live conference call Q&A, please register at https://register.vevent.com/register/BI289df7d30f474a72a72e1c4f7a754c92. To\nlisten to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/6gd5c9ve. The live and archived webcast can\nbe accessed in the Investors section of the Company\u2019s website, IR.Iovance.com. The archived webcast will be available for one year.\n\nAbout Iovance Biotherapeutics, Inc.\n\nIovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for\npatients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system\u2019s ability to recognize\nand destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors.\nIovance\u2019s Amtagvi\u2122 is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell\ntherapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit\nwww.iovance.com.\n\nAmtagvi\u2122 and its accompanying design marks, Proleukin\u00ae, Iovance\u00ae, and IovanceCares\u2122 are trademarks and registered trademarks of Iovance\nBiotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.\n\nForward-Looking Statements\n\nCertain matters discussed in this press release are \u201cforward-looking statements\u201d of Iovance Biotherapeutics, Inc. (hereinafter referred to as the\n\u201cCompany,\u201d \u201cwe,\u201d \u201cus,\u201d or \u201cour\u201d) within the meaning of the Private Securities Litigation Reform Act of 1995 (the \u201cPSLRA\u201d). Without limiting the\nforegoing, we may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d\n\u201cintends,\u201d \u201cforecast,\u201d \u201cguidance,\u201d \u201coutlook,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d or other words that convey uncertainty of future events or\noutcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made\nin light of management\u2019s experience and perception of historical trends, current conditions, expected future developments, and other factors\nbelieved to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty\nto update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not\nguarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause\nactual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these\nforward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from\nforward-looking statements are described in the sections titled \"Risk Factors\" in our filings with the U.S. Securities and Exchange Commission,\nincluding our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following\nsubstantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our\nproducts, including Amtagvi and Proleukin, for which we obtain U.S. Food and Drug Administration (\u201cFDA\u201d), European Medicines Agency\n(\u201cEMA\u201d), or other regulatory authority approval\u037e the risk that the EMA or other regulatory authorities may not approve or may delay approval for\nour biologics license application (\u201cBLA\u201d) submission for lifileucel in metastatic melanoma\u037e the acceptance by the market of our products, including\nAmtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S.\nand other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products,\nincluding Amtagvi and Proleukin, or product candidates, respectively\u037e our ability or inability to manufacture our therapies using third party\nmanufacturers or at our own facility may adversely affect our commercial launch\u037e the results of clinical trials with collaborators using different\nmanufacturing processes may not be reflected in our sponsored trials\u037e the risk regarding the successful integration of the recent Proleukin\nacquisition\u037e the risk that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate\nsufficient revenue from product sales, and we may not become profitable in the near term, or at all\u037e the risk that future competitive or other market\nfactors may adversely affect the commercial potential for Amtagvi or Proleukin\u037e the risks related to the timing of and our ability to successfully\ndevelop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates\u037e\nwhether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support\nregistrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm\nPhase 2 IOV-LUN-202 trial may not support registration\u037e preliminary and interim clinical results, which may include efficacy and safety results, from\nongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other\nprior trials or cohorts\u037e the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other\nregulatory agency input\u037e the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication\u037e the\nrisk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA,\nor other regulatory authorities\u037e the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other\nregulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior\nmeetings with the FDA regarding our non-small cell lung cancer clinical trials)\u037e the risk that clinical data from ongoing clinical trials of Amtagvi will\nnot continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization\u037e the risk that\nunanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements\u037e the effects of the\nCOVID-19 pandemic\u037e and other factors, including general economic conditions and regulatory developments, not within our control.\n\f            Case 5:25-cv-04177-EKL                      Document 103-7                   Filed 06/15/26          Page 9 of 9\n\n\n                                                     IOVANCE BIOTHERAPEUTICS, INC.\n                                                     Selected Consolidated Balance Sheets\n                                                                (in thousands)\n\n                                                                                                             December 31,        December 31,\n                                                                                                                 2023                2022\nCash, cash equivalents, and investments                                                                     $       279,867     $      471,845\nRestricted cash                                                                                                      66,430               6,430\nTotal assets                                                                                                        780,351            663,982\nStockholders' equity                                                                                                584,613            499,638\n\n                                                   Consolidated Statements of Operations\n                                                (in thousands, except per share information)\n\n                                                                          For the Three Months Ended               For the Year Ended\n                                                                                 December 31,                        December 31,\n                                                                            2023              2022\n                                                                         (unaudited)       (unaudited)           2023                2022\nRevenue\n  Product revenue                                                    $            482     $           \u2014     $           1,189   $           \u2014\n    Total revenue                                                                 482                 \u2014                 1,189               \u2014\n\nCosts and expenses*\n Cost of sales                                                       $           4,365    $           \u2014     $        10,755     $            \u2014\n Research and development                                                       87,470            80,573            344,077             294,781\n Selling, general and administrative                                            29,903            26,463            106,916             104,097\n    Total costs and expenses                                                   121,738           107,036            461,748             398,878\n\nLoss from operations                                                          (121,256)         (107,036)          (460,559)           (398,878)\nOther income\n  Interest income, net                                                           3,118             1,717             13,043               2,985\nNet Loss before income taxes                                         $        (118,138) $       (105,319) $        (447,516) $         (395,893)\n  Income tax benefit                                                             1,759                \u2014               3,479                  \u2014\nNet Loss                                                             $        (116,379) $       (105,319) $        (444,037) $         (395,893)\nNet Loss Per Share of Common Stock, Basic and Diluted                $           (0.45) $          (0.64) $           (1.89) $            (2.49)\nWeighted-Average Shares of Common Stock Outstanding, Basic and\nDiluted                                                                        255,951           164,765            235,131             159,259\n\n*Includes stock-based compensation as follows:\n  Research and development                                           $           7,890    $       11,379    $        34,926     $        50,242\n  Selling, general and administrative                                            6,509             8,130             27,699              33,780\n    Total stock-based compensation included in costs and expenses    $          14,399    $       19,509    $        62,625     $        84,022\n\n\nCONTACTS\n\nIovance Biotherapeutics, Inc.:\nSara Pellegrino, IRC\nSVP, Investor Relations & Corporate Communications\n650-260-7120 ext. 264\nSara.Pellegrino@iovance.com\n\nJen Saunders\nSenior Director, Investor Relations & Corporate Communications\n267-485-3119\nJen.Saunders@iovance.com\n\f","ocr_status":1,"date_upload":"2026-06-16T16:05:22.655281-07:00","document_number":"103","attachment_number":7,"pacer_doc_id":"035027255230","is_available":true,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 5 - 2024.02.28  8-K Ex. 99.1","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798505/","id":482798505,"tags":[],"absolute_url":"/docket/70274365/103/8/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:03.564470-07:00","date_modified":"2026-06-15T15:39:03.564488-07:00","sha1":"","page_count":19,"file_size":404783,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":8,"pacer_doc_id":"035027255231","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 6 - 2024.02.28 Q4 2023 Earnings Call","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798509/","id":482798509,"tags":[],"absolute_url":"/docket/70274365/103/9/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:03.788271-07:00","date_modified":"2026-06-15T15:39:03.788294-07:00","sha1":"","page_count":85,"file_size":655587,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":9,"pacer_doc_id":"035027255232","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 7 - 2024.02.28  10-K FY 2023","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798512/","id":482798512,"tags":[],"absolute_url":"/docket/70274365/103/10/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:03.969307-07:00","date_modified":"2026-06-15T15:39:03.969327-07:00","sha1":"","page_count":10,"file_size":238009,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":10,"pacer_doc_id":"035027255233","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 8 - 2024.05.09  8-K Ex. 99.1","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798514/","id":482798514,"tags":[],"absolute_url":"/docket/70274365/103/11/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:04.161908-07:00","date_modified":"2026-06-15T15:39:04.161929-07:00","sha1":"","page_count":19,"file_size":412480,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":11,"pacer_doc_id":"035027255234","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 9 - 2024.05.09  Q1 2024 Earnings Call","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798515/","id":482798515,"tags":[],"absolute_url":"/docket/70274365/103/12/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:04.307875-07:00","date_modified":"2026-06-15T15:39:04.307918-07:00","sha1":"","page_count":59,"file_size":519776,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":12,"pacer_doc_id":"035027255235","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 10 - 2024.05.09  10-Q Q1 2024","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798516/","id":482798516,"tags":[],"absolute_url":"/docket/70274365/103/13/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:04.454023-07:00","date_modified":"2026-06-15T15:39:04.454093-07:00","sha1":"","page_count":12,"file_size":245282,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":13,"pacer_doc_id":"035027255236","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 11 - 2024.08.08  8K Ex. 99.1","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798517/","id":482798517,"tags":[],"absolute_url":"/docket/70274365/103/14/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:04.574065-07:00","date_modified":"2026-06-15T15:39:04.574081-07:00","sha1":"","page_count":19,"file_size":430281,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":14,"pacer_doc_id":"035027255237","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 12 - 2024.08.08  Q2 2024 Earnings Call","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798518/","id":482798518,"tags":[],"absolute_url":"/docket/70274365/103/15/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:04.676701-07:00","date_modified":"2026-06-15T15:39:04.676722-07:00","sha1":"","page_count":60,"file_size":524895,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":15,"pacer_doc_id":"035027255238","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 13 - 2024.08.08  10-Q Q2 2024","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798519/","id":482798519,"tags":[],"absolute_url":"/docket/70274365/103/16/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:04.789308-07:00","date_modified":"2026-06-15T15:39:04.789331-07:00","sha1":"","page_count":14,"file_size":256384,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":16,"pacer_doc_id":"035027255239","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 14 - 2024.11.07  8-K Ex. 99.1","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798520/","id":482798520,"tags":[],"absolute_url":"/docket/70274365/103/17/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:04.880190-07:00","date_modified":"2026-06-15T15:39:04.880214-07:00","sha1":"","page_count":18,"file_size":412712,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":17,"pacer_doc_id":"035027255240","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 15 - 2024.11.07  Q3 2024 Earnings Call","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798521/","id":482798521,"tags":[],"absolute_url":"/docket/70274365/103/18/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:04.955554-07:00","date_modified":"2026-06-15T15:39:04.955577-07:00","sha1":"","page_count":62,"file_size":535644,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":18,"pacer_doc_id":"035027255241","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 16 - 2024.11.07  10-Q Q3 2024","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798522/","id":482798522,"tags":[],"absolute_url":"/docket/70274365/103/19/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:05.024113-07:00","date_modified":"2026-06-15T15:39:05.024134-07:00","sha1":"","page_count":12,"file_size":252074,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":19,"pacer_doc_id":"035027255242","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 17 - 2025.02.27  8-K Ex. 99.1","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798523/","id":482798523,"tags":[],"absolute_url":"/docket/70274365/103/20/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:05.096338-07:00","date_modified":"2026-06-15T15:39:05.096360-07:00","sha1":"","page_count":18,"file_size":416117,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":20,"pacer_doc_id":"035027255243","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 18 - 2025.02.27  Q4 2024 Earnings Call","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798524/","id":482798524,"tags":[],"absolute_url":"/docket/70274365/103/21/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:05.175841-07:00","date_modified":"2026-06-15T15:39:05.175863-07:00","sha1":"","page_count":88,"file_size":671326,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":21,"pacer_doc_id":"035027255244","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 19 - 2025.02.27  10-K FY 2024","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798525/","id":482798525,"tags":[],"absolute_url":"/docket/70274365/103/22/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:05.257598-07:00","date_modified":"2026-06-15T15:39:05.257620-07:00","sha1":"","page_count":13,"file_size":244533,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":22,"pacer_doc_id":"035027255245","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 20 - 2025.05.08  8-K Ex.99.1","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798526/","id":482798526,"tags":[],"absolute_url":"/docket/70274365/103/23/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:05.339388-07:00","date_modified":"2026-06-15T15:39:05.339408-07:00","sha1":"","page_count":21,"file_size":418437,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":23,"pacer_doc_id":"035027255246","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 21 - 2025.05.08  Q1 Earnings Call","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798527/","id":482798527,"tags":[],"absolute_url":"/docket/70274365/103/24/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:05.391119-07:00","date_modified":"2026-06-15T15:39:05.391142-07:00","sha1":"","page_count":64,"file_size":544566,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":24,"pacer_doc_id":"035027255247","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Exhibit 22 - 2025.05.08  10Q Q1 2025","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798528/","id":482798528,"tags":[],"absolute_url":"/docket/70274365/103/25/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:05.469144-07:00","date_modified":"2026-06-15T15:39:05.469168-07:00","sha1":"","page_count":4,"file_size":187137,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":25,"pacer_doc_id":"035027255248","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Request for Judicial Notice","acms_document_guid":""},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482798529/","id":482798529,"tags":[],"absolute_url":"/docket/70274365/103/26/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T15:39:05.525785-07:00","date_modified":"2026-06-15T15:39:05.525801-07:00","sha1":"","page_count":2,"file_size":152290,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"103","attachment_number":26,"pacer_doc_id":"035027255249","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":2,"description":"Proposed Order","acms_document_guid":""}],"date_created":"2026-06-15T13:32:52.385497-07:00","date_modified":"2026-10-15T06:59:54.654150-07:00","date_filed":"2026-06-15","time_filed":"13:25:20","entry_number":103,"recap_sequence_number":"2026-06-15.002","pacer_sequence_number":423,"description":"MOTION to Dismiss Consolidated Amended Complaint for Violations of The Federal Securities Laws filed by Jean-Marc Bellemin, Igor P. Bilinsky, Iovance Biotherapeutics, Inc., Frederick G. Vogt, James Zeigler. Motion to Dismiss Hearing set for 10/7/2026 10:00 AM in San Jose, Courtroom 7, 4th Floor. Responses due by 8/14/2026. Replies due by 9/14/2026. (Attachments: # 1 Appendix, # 2 Declaration of Veronica Callahan, # 3 Exhibit 1 - 2023.11.07 8-K, Ex.99.1, # 4 Exhibit 2 - 2023.11.07 Q3 2023 Earnings Call, # 5 Exhibit 3 - 2023.11.07 10-Q Q3 2023, # 6 Exhibit 4 - 2024.02.16 Investor Call, # 7 Exhibit 5 - 2024.02.28 8-K Ex. 99.1, # 8 Exhibit 6 - 2024.02.28 Q4 2023 Earnings Call, # 9 Exhibit 7 - 2024.02.28 10-K FY 2023, # 10 Exhibit 8 - 2024.05.09 8-K Ex. 99.1, # 11 Exhibit 9 - 2024.05.09 Q1 2024 Earnings Call, # 12 Exhibit 10 - 2024.05.09 10-Q Q1 2024, # 13 Exhibit 11 - 2024.08.08 8K Ex. 99.1, # 14 Exhibit 12 - 2024.08.08 Q2 2024 Earnings Call, # 15 Exhibit 13 - 2024.08.08 10-Q Q2 2024, # 16 Exhibit 14 - 2024.11.07 8-K Ex. 99.1, # 17 Exhibit 15 - 2024.11.07 Q3 2024 Earnings Call, # 18 Exhibit 16 - 2024.11.07 10-Q Q3 2024, # 19 Exhibit 17 - 2025.02.27 8-K Ex. 99.1, # 20 Exhibit 18 - 2025.02.27 Q4 2024 Earnings Call, # 21 Exhibit 19 - 2025.02.27 10-K FY 2024, # 22 Exhibit 20 - 2025.05.08 8-K Ex.99.1, # 23 Exhibit 21 - 2025.05.08 Q1 Earnings Call, # 24 Exhibit 22 - 2025.05.08 10Q Q1 2025, # 25 Request for Judicial Notice, # 26 Proposed Order)(Huynh, Tommy) (Filed on 6/15/2026) Modified on 7/8/2026 (lrt, COURT STAFF). (Entered: 06/15/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/467497058/","id":467497058,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/482762567/","id":482762567,"tags":[],"absolute_url":"/docket/70274365/102/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-06-15T13:01:51.857684-07:00","date_modified":"2026-06-15T13:01:51.870779-07:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"102","attachment_number":null,"pacer_doc_id":"035027255023","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Notice of Change of Address","acms_document_guid":""}],"date_created":"2026-06-15T13:01:51.824236-07:00","date_modified":"2026-10-15T06:59:54.632747-07:00","date_filed":"2026-06-15","time_filed":"12:53:41","entry_number":102,"recap_sequence_number":"2026-06-15.001","pacer_sequence_number":420,"description":"NOTICE of Change of Address by Tommy Huynh (Huynh, Tommy) (Filed on 6/15/2026) (Entered: 06/15/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/460914179/","id":460914179,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/475991745/","id":475991745,"tags":[],"absolute_url":"/docket/70274365/101/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-04-15T16:35:33.207687-07:00","date_modified":"2026-04-15T16:35:33.216939-07:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"101","attachment_number":null,"pacer_doc_id":"035027006218","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Amended Complaint","acms_document_guid":""}],"date_created":"2026-04-15T16:35:33.185118-07:00","date_modified":"2026-10-15T06:59:54.613166-07:00","date_filed":"2026-04-15","time_filed":"16:26:12","entry_number":101,"recap_sequence_number":"2026-04-15.001","pacer_sequence_number":417,"description":"AMENDED COMPLAINT against Jean-Marc Bellemin, Igor P. Bilinsky, Iovance Biotherapeutics, Inc., Frederick G. Vogt, James Zeigler. Filed by Tony Djie, Lindy Merrill. (Fuks, Sara) (Filed on 4/15/2026) (Entered: 04/15/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/455554496/","id":455554496,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/470501076/","id":470501076,"tags":[],"absolute_url":"/docket/70274365/99/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-03-02T13:04:23.595524-08:00","date_modified":"2026-03-02T13:04:23.603685-08:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"99","attachment_number":null,"pacer_doc_id":"035026819842","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Stipulation and Proposed Order","acms_document_guid":""}],"date_created":"2026-03-02T13:04:23.562970-08:00","date_modified":"2026-10-15T06:59:54.570252-07:00","date_filed":"2026-03-02","time_filed":"12:57:46","entry_number":99,"recap_sequence_number":"2026-03-02.001","pacer_sequence_number":410,"description":"STIPULATION WITH PROPOSED ORDER Joint Stipulation and Proposed Order Extending Deadlines for Pleading and Briefing Schedule filed by Tony Djie, Lindy Merrill. (Fuks, Sara) (Filed on 3/2/2026) (Entered: 03/02/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/451940719/","id":451940719,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/466796671/","id":466796671,"tags":[],"absolute_url":"/docket/70274365/98/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-01-28T18:04:48.058552-08:00","date_modified":"2026-05-18T05:32:32.853236-07:00","sha1":"61cc0878624d003c9aac50bb71c0f011aa1c5745","page_count":2,"file_size":1512854,"filepath_local":"recap/gov.uscourts.cand.449628/gov.uscourts.cand.449628.98.0.pdf","filepath_ia":"https://archive.org/download/gov.uscourts.cand.449628/gov.uscourts.cand.449628.98.0.pdf","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"           Case 5:25-cv-04177-EKL     Document 98   Filed 01/28/26   Page 1 of 2\n\n\n\n\n 1\n 2\n 3\n 4\n 5\n 6                          UNITED STATES DISTRICT COURT\n                          NORTHERN DISTRICT OF CALIFORNIA\n 7                                SAN JOSE DIVISION\n 8\n 9                                           Case No. 5:25-cv-04177-EKL-NMC\n     In re IOVANCE BIOTHERAPEUTICS,\n10   INC. SECURITIES LITIGATION              CLASS ACTION\n11\n     This Document Relates To:               [PROPOSED] ORDER GRANTING REQUEST\n12         ALL ACTIONS                       FOR WITHDRAWAL OF COUNSEL\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n\n\n     [PROPOSED] ORDER\n     CASE NO. 5:25-CV-04177-EKL-NMC\n\f             Case 5:25-cv-04177-EKL        Document 98      Filed 01/28/26     Page 2 of 2\n\n\n\n\n 1           Upon consideration of the Notice of Request for Withdrawal of Counsel, and for good cause\n 2   shown, it is HEREBY ORDERED that Javier Bleichmar, Lesley E. Weaver, Ross Shikowitz, and Adam\n 3   C. McCall of Bleichmar Fonti & Auld LLP are hereby withdrawn as counsel of record. The clerk is\n 4   directed to remove the above-named attorneys and law firm from the docket as well as the ECF Service\n 5   List.\n 6\n     IT IS SO ORDERED.\n 7\n 8\n                      January 28\n     Dated: _________________________, 2026\n 9\n10\n11                                                            HON. EUMI K. LEE\n                                                        UNITED STATES DISTRICT JUDGE\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n\n\n     [PROPOSED] ORDER\n     CASE NO. 5:25-CV-04177-EKL-NMC\n\f","ocr_status":2,"date_upload":"2026-05-14T23:31:33.259503-07:00","document_number":"98","attachment_number":null,"pacer_doc_id":"035026699071","is_available":true,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Order on Motion to Withdraw as Attorney","acms_document_guid":""}],"date_created":"2026-01-28T18:04:48.022153-08:00","date_modified":"2026-10-15T06:59:54.546730-07:00","date_filed":"2026-01-28","time_filed":"17:36:27","entry_number":98,"recap_sequence_number":"2026-01-28.001","pacer_sequence_number":408,"description":"ORDER granting 96 Request for Withdrawal of Counsel. Attorneys Javier Bleichmar, Lesley E. Weaver, Ross Shikowitz, and Adam C. McCall withdrawn. Signed by Judge Eumi K. Lee (lrt, COURT STAFF) (Filed on 1/28/2026) (Entered: 01/28/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/450876667/","id":450876667,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/465706043/","id":465706043,"tags":[],"absolute_url":"/docket/70274365/97/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-01-20T12:35:08.612454-08:00","date_modified":"2026-02-23T04:17:32.105181-08:00","sha1":"d67001d7d438657a0d433e41b3a21f7ba815575c","page_count":4,"file_size":1581742,"filepath_local":"recap/gov.uscourts.cand.449628/gov.uscourts.cand.449628.97.0.pdf","filepath_ia":"https://archive.org/download/gov.uscourts.cand.449628/gov.uscourts.cand.449628.97.0.pdf","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"         Case 5:25-cv-04177-EKL          Document 97     Filed 01/20/26   Page 1 of 4\n\n\n\n 1   THE ROSEN LAW FIRM, P.A.\n     Laurence M. Rosen (SBN 219683)\n 2   355 South Grand Avenue, Suite 2450\n     Los Angeles, CA 90071\n 3   Telephone: (213) 785-2610\n     Facsimile: (213) 226-4684\n 4   Email: lrosen@rosenlegal.com\n\n 5   [Additional Counsel on Signature Page]\n\n 6\n\n 7\n\n 8                                UNITED STATES DISTRICT COURT\n\n 9                             NORTHERN DISTRICT OF CALIFORNIA\n\n10                                               SAN JOSE\n\n11\n\n12                                                     Case No.: 5:25-cv-04177-EKL\n     In re Iovance Biotherapeutics, Inc. Securities\n13   Litigation\n                                                       JOINT STIPULATION AND\n14                                                     [PROPOSED] ORDER REGARDING\n                                                       CASE SCHEDULE\n15\n\n16\n                                                       Judge:    Hon. Eumi K. Lee\n17                                                     Courtroom: 7 \u2013 4th Floor\n\n18\n\n19\n\n20\n\n21\n\n22\n\n23\n\n24\n\n25\n\n26\n\n27\n\n28\n\n     JOINT STIPULATION AND [PROPOSED]                                 CASE NO. 5:25-cv-04177-EKL\n     ORDER RE CASE SCHEDULE\n\f         Case 5:25-cv-04177-EKL             Document 97         Filed 01/20/26     Page 2 of 4\n\n\n\n 1            Court appointed Lead Plaintiff Lindy Merrill and Tony Djie (\u201cPlaintiff\u201d) and Defendants\n\n 2   Iovance Biotherapeutics, Inc., Frederick G. Vogt, Jean-Marc Bellemin, Igor Bilinksy, and Daniel G.\n\n 3   Kirby (collectively, \u201cDefendants\u201d), by and through their respective counsel, respectfully submit this\n\n 4   Stipulation and [Proposed] Order setting forth a schedule for the filing of an amended complaint, a\n\n 5   motion to dismiss, an opposition to the motion to dismiss, and a reply to the opposition to the motion\n\n 6   to dismiss.\n\n 7            WHEREAS, on December 15, 2025, the Court entered an Order Appointing Lead Plaintiff\n\n 8   and Lead Counsel which requires the parties to submit a proposed schedule for the filing of a\n\n 9   consolidated or amended complaint and Defendants\u2019 responsive pleading within thirty days [Docket\n\n10   No. 92];\n\n 1            WHEREAS, Plaintiff presently intends to file an amended complaint;\n\n13            WHEREAS, the Defendants presently intend to move to dismiss any complaint in this action;\n\n14            WHEREAS, pursuant to the PSLRA, all discovery and other proceedings in this action are\n\n15   stayed pending the determination of the Defendants\u2019 planned motion to dismiss;\n\n16            NOW, THEREFORE, Plaintiff and the Defendants stipulate and agree, subject to approval\n\n17   of the Court, as follows:\n\n18                         1. Plaintiff shall file an amended complaint (the \u201cCAC\u201d) by March 16, 2026;\n\n19                         2. The Defendants shall answer or otherwise respond to the CAC by May 15,\n\n20                 2026;\n\n21                         3. If a motion to dismiss is filed, Plaintiff shall file any opposition by July 14,\n\n22                 2026;\n\n23                         4. The Defendants shall file any reply by August 13, 2026.\n\n24\n     Dated:        January 14, 2026                        THE ROSEN LAW FIRM, P.A.\n25                                                         Laurence M. Rosen (SBN 219683)\n                                                           355 South Grand Avenue, Suite 2450\n26                                                         Los Angeles, CA 90071\n                                                           Telephone: (213) 785-2610\n27                                                         Facsimile: (213) 225-4684\n                                                           Email: lrosen@rosenlegal.com\n28\n\n\n\n     STIPULATION AND [PROPOSED]                                                CASE NO. 5:25-cv-04177-EKL\n     ORDER RE CASE SCHEDULE                                 1\n\f         Case 5:25-cv-04177-EKL   Document 97       Filed 01/20/26       Page 3 of 4\n\n\n\n 1                                          THE ROSEN LAW FIRM, P.A.\n                                            Phillip C. Kim (admitted pro hac vice)\n 2                                          Sara Fuks (admitted pro hac vice)\n                                            275 Madison Avenue- 40th Floor\n 3                                          New York, NY 10016\n                                            Telephone: (212) 686-1060\n 4                                          Email: sfuks@rosenlegal.com\n\n 5                                          By:       /s/ Sara Fuks\n                                                      Sara Fuks\n 6\n\n 7\n                                            Lead Counsel for Lead Plaintiff and the Class\n 8\n                                            THE SCHALL LAW FIRM\n 9\n                                            Brian Schall (290685)\n10                                          2049 Century Park East, Suite 2460\n                                            Los Angeles, CA 90067\n 1                                          Telephone: (310) 301-3335\n                                            brian@schallfirm.com\n13\n                                            Additional Counsel for Lead Plaintiff and the\n14                                          Class\n15   Dated:   January 14, 2026              ARNOLD & PORTER KAYE SCHOLER\n                                            LLP\n16                                          Tommy Huynh\n                                            Three Embarcadero Center, 10th Floor\n17                                          San Francisco, CA 94111\n                                            Telephone: +1 415 471 3147\n18                                          Facsimile: +1 415 471 3400\n                                            tommy.huynh@arnoldporter.com\n19\n                                            ARNOLD & PORTER KAYE SCHOLER\n20                                          LLP\n                                            Aaron Frank Miner- admitted pro hac vice\n21                                          Veronica E. Callahan- admitted pro hac vice\n                                            250 West 55th Street\n22                                          New York, NY 10019\n                                            Telephone: + 212-836-8000\n23                                          Aaron.Miner@arnoldporter.com\n                                            veronica.callahan@arnoldporter.com\n24\n                                            ARNOLD & PORTER KAYE SCHOLER\n25                                          LLP\n                                            Stephanna F. Szotkowski-admitted pro hac vice\n26                                          70 West Madison Street\n                                            Suite 4200\n27                                          Chicago, IL 60602\n                                            Telephone: 312-583-2354\n28                                          Stephanna.Szotkowski@arnoldporter.com\n\n\n\n     STIPULATION AND [PROPOSED]                                       CASE NO. 5:25-cv-04177-EKL\n     ORDER RE CASE SCHEDULE                     2\n\f         Case 5:25-cv-04177-EKL          Document 97          Filed 01/20/26     Page 4 of 4\n\n\n\n 1\n\n 2\n\n 3                                                      By:     /s/ Tommy Huynh\n\n 4\n                                                        Counsel for Defendants Iovance\n 5                                                      Biotherapeutics, Inc., Frederick Vogt, Jean-\n                                                        Marc Bellemin, Igor P. Bilinsky, and Daniel G.\n 6                                                      Kirby\n 7\n\n 8\n                                      SIGNATURE ATTESTATION\n 9\n            Pursuant to Local Civil Rule 5-1(h)(3), I attest under penalty of perjury that each of the other\n10\n     signatories have concurred in the filing of this document.\n 1\n            January 14, 2026                              By: /s/ Sara Fuks\n13\n                                                                  Sara Fuks\n14\n\n15   IT IS SO ORDERED\n16\n\n17\n             January 20\n     Dated: ______________, 2026\n18                                                        Hon. Eumi K. Lee\n                                                          United States District Court Judge\n19\n\n20\n\n21\n\n22\n\n23\n\n24\n\n25\n\n26\n\n27\n\n28\n\n\n\n     STIPULATION AND [PROPOSED]                                               CASE NO. 5:25-cv-04177-EKL\n     ORDER RE CASE SCHEDULE                              3\n\f","ocr_status":2,"date_upload":"2026-02-17T08:09:45.608344-08:00","document_number":"97","attachment_number":null,"pacer_doc_id":"035026661604","is_available":true,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Order on Stipulation","acms_document_guid":""}],"date_created":"2026-01-20T12:35:08.588209-08:00","date_modified":"2026-01-27T00:03:51.677182-08:00","date_filed":"2026-01-20","time_filed":"12:13:15","entry_number":97,"recap_sequence_number":"2026-01-20.001","pacer_sequence_number":406,"description":"ORDER granting 95 Joint Stipulation Regarding Case Schedule. Signed by Judge Eumi K. Lee. (lrt, COURT STAFF) (Filed on 1/20/2026) (Entered: 01/20/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/450332428/","id":450332428,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/465147277/","id":465147277,"tags":[],"absolute_url":"/docket/70274365/96/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-01-14T13:04:24.805913-08:00","date_modified":"2026-01-27T00:03:51.650778-08:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"96","attachment_number":null,"pacer_doc_id":"035026643981","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Notice (Other)","acms_document_guid":""}],"date_created":"2026-01-14T13:04:24.781023-08:00","date_modified":"2026-01-27T00:03:51.582606-08:00","date_filed":"2026-01-14","time_filed":"12:37:50","entry_number":96,"recap_sequence_number":"2026-01-14.002","pacer_sequence_number":404,"description":"NOTICE by Brian Paplaski of Request for Withdrawal of Counsel (Attachments: # 1 Exhibit A - Proposed Order)(Weaver, Lesley) (Filed on 1/14/2026) (Entered: 01/14/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/450298001/","id":450298001,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/465112220/","id":465112220,"tags":[],"absolute_url":"/docket/70274365/95/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-01-14T10:35:50.070601-08:00","date_modified":"2026-02-16T06:56:56.897779-08:00","sha1":"045dfa5e8e7ee49678ff27378e8c525835b27d8b","page_count":4,"file_size":189678,"filepath_local":"recap/gov.uscourts.cand.449628/gov.uscourts.cand.449628.95.0.pdf","filepath_ia":"https://archive.org/download/gov.uscourts.cand.449628/gov.uscourts.cand.449628.95.0.pdf","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"         Case 5:25-cv-04177-EKL          Document 95     Filed 01/14/26   Page 1 of 4\n\n\n\n 1   THE ROSEN LAW FIRM, P.A.\n     Laurence M. Rosen (SBN 219683)\n 2   355 South Grand Avenue, Suite 2450\n     Los Angeles, CA 90071\n 3   Telephone: (213) 785-2610\n     Facsimile: (213) 226-4684\n 4   Email: lrosen@rosenlegal.com\n\n 5   [Additional Counsel on Signature Page]\n\n 6\n\n 7\n\n 8                                UNITED STATES DISTRICT COURT\n\n 9                             NORTHERN DISTRICT OF CALIFORNIA\n\n10                                               SAN JOSE\n\n11\n\n12                                                     Case No.: 5:25-cv-04177-EKL\n     In re Iovance Biotherapeutics, Inc. Securities\n13   Litigation\n                                                       JOINT STIPULATION AND\n14                                                     [PROPOSED] ORDER REGARDING\n                                                       CASE SCHEDULE\n15\n\n16\n                                                       Judge:    Hon. Eumi K. Lee\n17                                                     Courtroom: 7 \u2013 4th Floor\n\n18\n\n19\n\n20\n\n21\n\n22\n\n23\n\n24\n\n25\n\n26\n\n27\n\n28\n\n     JOINT STIPULATION AND [PROPOSED]                                 CASE NO. 5:25-cv-04177-EKL\n     ORDER RE CASE SCHEDULE\n\f         Case 5:25-cv-04177-EKL             Document 95         Filed 01/14/26     Page 2 of 4\n\n\n\n 1            Court appointed Lead Plaintiff Lindy Merrill and Tony Djie (\u201cPlaintiff\u201d) and Defendants\n\n 2   Iovance Biotherapeutics, Inc., Frederick G. Vogt, Jean-Marc Bellemin, Igor Bilinksy, and Daniel G.\n\n 3   Kirby (collectively, \u201cDefendants\u201d), by and through their respective counsel, respectfully submit this\n\n 4   Stipulation and [Proposed] Order setting forth a schedule for the filing of an amended complaint, a\n\n 5   motion to dismiss, an opposition to the motion to dismiss, and a reply to the opposition to the motion\n\n 6   to dismiss.\n\n 7            WHEREAS, on December 15, 2025, the Court entered an Order Appointing Lead Plaintiff\n\n 8   and Lead Counsel which requires the parties to submit a proposed schedule for the filing of a\n\n 9   consolidated or amended complaint and Defendants\u2019 responsive pleading within thirty days [Docket\n\n10   No. 92];\n\n 1            WHEREAS, Plaintiff presently intends to file an amended complaint;\n\n13            WHEREAS, the Defendants presently intend to move to dismiss any complaint in this action;\n\n14            WHEREAS, pursuant to the PSLRA, all discovery and other proceedings in this action are\n\n15   stayed pending the determination of the Defendants\u2019 planned motion to dismiss;\n\n16            NOW, THEREFORE, Plaintiff and the Defendants stipulate and agree, subject to approval\n\n17   of the Court, as follows:\n\n18                         1. Plaintiff shall file an amended complaint (the \u201cCAC\u201d) by March 16, 2026;\n\n19                         2. The Defendants shall answer or otherwise respond to the CAC by May 15,\n\n20                 2026;\n\n21                         3. If a motion to dismiss is filed, Plaintiff shall file any opposition by July 14,\n\n22                 2026;\n\n23                         4. The Defendants shall file any reply by August 13, 2026.\n\n24\n     Dated:        January 14, 2026                        THE ROSEN LAW FIRM, P.A.\n25                                                         Laurence M. Rosen (SBN 219683)\n                                                           355 South Grand Avenue, Suite 2450\n26                                                         Los Angeles, CA 90071\n                                                           Telephone: (213) 785-2610\n27                                                         Facsimile: (213) 225-4684\n                                                           Email: lrosen@rosenlegal.com\n28\n\n\n\n     STIPULATION AND [PROPOSED]                                                CASE NO. 5:25-cv-04177-EKL\n     ORDER RE CASE SCHEDULE                                 1\n\f         Case 5:25-cv-04177-EKL   Document 95       Filed 01/14/26       Page 3 of 4\n\n\n\n 1                                          THE ROSEN LAW FIRM, P.A.\n                                            Phillip C. Kim (admitted pro hac vice)\n 2                                          Sara Fuks (admitted pro hac vice)\n                                            275 Madison Avenue- 40th Floor\n 3                                          New York, NY 10016\n                                            Telephone: (212) 686-1060\n 4                                          Email: sfuks@rosenlegal.com\n\n 5                                          By:       /s/ Sara Fuks\n                                                      Sara Fuks\n 6\n\n 7\n                                            Lead Counsel for Lead Plaintiff and the Class\n 8\n                                            THE SCHALL LAW FIRM\n 9\n                                            Brian Schall (290685)\n10                                          2049 Century Park East, Suite 2460\n                                            Los Angeles, CA 90067\n 1                                          Telephone: (310) 301-3335\n                                            brian@schallfirm.com\n13\n                                            Additional Counsel for Lead Plaintiff and the\n14                                          Class\n15   Dated:   January 14, 2026              ARNOLD & PORTER KAYE SCHOLER\n                                            LLP\n16                                          Tommy Huynh\n                                            Three Embarcadero Center, 10th Floor\n17                                          San Francisco, CA 94111\n                                            Telephone: +1 415 471 3147\n18                                          Facsimile: +1 415 471 3400\n                                            tommy.huynh@arnoldporter.com\n19\n                                            ARNOLD & PORTER KAYE SCHOLER\n20                                          LLP\n                                            Aaron Frank Miner- admitted pro hac vice\n21                                          Veronica E. Callahan- admitted pro hac vice\n                                            250 West 55th Street\n22                                          New York, NY 10019\n                                            Telephone: + 212-836-8000\n23                                          Aaron.Miner@arnoldporter.com\n                                            veronica.callahan@arnoldporter.com\n24\n                                            ARNOLD & PORTER KAYE SCHOLER\n25                                          LLP\n                                            Stephanna F. Szotkowski-admitted pro hac vice\n26                                          70 West Madison Street\n                                            Suite 4200\n27                                          Chicago, IL 60602\n                                            Telephone: 312-583-2354\n28                                          Stephanna.Szotkowski@arnoldporter.com\n\n\n\n     STIPULATION AND [PROPOSED]                                       CASE NO. 5:25-cv-04177-EKL\n     ORDER RE CASE SCHEDULE                     2\n\f         Case 5:25-cv-04177-EKL          Document 95          Filed 01/14/26     Page 4 of 4\n\n\n\n 1\n\n 2\n\n 3                                                      By:     /s/ Tommy Huynh\n\n 4\n                                                        Counsel for Defendants Iovance\n 5                                                      Biotherapeutics, Inc., Frederick Vogt, Jean-\n                                                        Marc Bellemin, Igor P. Bilinsky, and Daniel G.\n 6                                                      Kirby\n 7\n\n 8\n                                      SIGNATURE ATTESTATION\n 9\n            Pursuant to Local Civil Rule 5-1(h)(3), I attest under penalty of perjury that each of the other\n10\n     signatories have concurred in the filing of this document.\n 1\n            January 14, 2026                              By: /s/ Sara Fuks\n13\n                                                                  Sara Fuks\n14\n\n15   IT IS SO ORDERED\n16\n\n17\n     Dated: ______________, 2026\n18                                                        Hon. Eumi K. Lee\n                                                          United States District Court Judge\n19\n\n20\n\n21\n\n22\n\n23\n\n24\n\n25\n\n26\n\n27\n\n28\n\n\n\n     STIPULATION AND [PROPOSED]                                               CASE NO. 5:25-cv-04177-EKL\n     ORDER RE CASE SCHEDULE                              3\n\f","ocr_status":2,"date_upload":"2026-02-13T11:37:14.989154-08:00","document_number":"95","attachment_number":null,"pacer_doc_id":"035026642805","is_available":true,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Stipulation and Proposed Order","acms_document_guid":""}],"date_created":"2026-01-14T10:35:50.042867-08:00","date_modified":"2026-01-27T00:03:51.524332-08:00","date_filed":"2026-01-14","time_filed":"10:12:57","entry_number":95,"recap_sequence_number":"2026-01-14.001","pacer_sequence_number":402,"description":"STIPULATION WITH PROPOSED ORDER Joint Stipulation Regarding Proposed Case Schedule filed by Tony Djie, Lindy Merrill. (Fuks, Sara) (Filed on 1/14/2026) (Entered: 01/14/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/450084570/","id":450084570,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/464893804/","id":464893804,"tags":[],"absolute_url":"/docket/70274365/94/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-01-12T16:03:44.516997-08:00","date_modified":"2026-05-18T05:23:44.088837-07:00","sha1":"4c419e47ade067c85e41e4f37261406eddab1984","page_count":2,"file_size":1506441,"filepath_local":"recap/gov.uscourts.cand.449628/gov.uscourts.cand.449628.94.0.pdf","filepath_ia":"https://archive.org/download/gov.uscourts.cand.449628/gov.uscourts.cand.449628.94.0.pdf","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"                                        Case 5:25-cv-04177-EKL                    Document 94       Filed 01/12/26           Page 1 of 2\n\n\n\n\n                                   1                                         UNITED STATES DISTRICT COURT\n\n                                   2                                     NORTHERN DISTRICT OF CALIFORNIA\n\n                                   3\n\n                                   4                                                                Case No. 5:25-cv-04177-EKL\n\n                                   5     IN RE IOVANCE BIOTHERAPEUTICS,\n                                         INC. SECURITIES LITIGATION                                 APPLICATION FOR ADMISSION OF\n                                   6                                                                ATTORNEY PRO HAC VICE\n                                                                                                    (CIVIL LOCAL RULE 11-3)\n                                   7\n\n                                   8\n\n                                   9\n\n                                  10            I,            Sara Fuks               , an active member in good standing of the bar of\n\n                                  11                 New York State                   , hereby respectfully apply for admission to practice pro hac\n\n                                  12   vice in the Northern District of California representing:            Plaintiffs Lindy Merrill and Tony Djie      in the\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13   above-entitled action. My local co-counsel in this case is                  Laurence M. Rosen                   , an\n\n                                  14   attorney who is a member of the bar of this Court in good standing and who maintains an office\n\n                                  15   within the State of California. Local co-counsel\u2019s bar number is: _________________.\n                                                                                                           SBN 219683\n\n                                  16   275 Madison Ave, 40th Fl, New York, NY 10016                 355 South Grand Ave, Suite 2450, Los Angeles, CA 90071\n\n                                  17    MY ADDRESS OF RECORD                                         LOCAL CO-COUNSEL\u2019S ADDRESS OF RECORD\n\n                                  18   (212) 686-1060                                                (213) 785-2610\n                                        MY TELEPHONE # OF RECORD                                     LOCAL CO-COUNSEL\u2019S TELEPHONE # OF RECORD\n                                  19\n                                       sfuks@rosenlegal.com                                         lrosen@rosenlegal.com\n                                  20    MY EMAIL ADDRESS OF RECORD                                   LOCAL CO-COUNSEL\u2019S EMAIL ADDRESS OF RECORD\n\n                                  21\n\n                                  22            I am an active member in good standing of a United States Court or of the highest court of\n                                  23   another State or the District of Columbia, as indicated above; my bar number is: 4353249                                  .\n                                  24            A true and correct copy of a certificate of good standing or equivalent official document\n                                  25   from said bar is attached to this application.\n                                  26                                                                      zero times in the 12 months\n                                                I have been granted pro hac vice admission by the Court _______\n                                  27   preceding this application.\n                                  28\n\f                                         Case 5:25-cv-04177-EKL           Document 94        Filed 01/12/26      Page 2 of 2\n\n\n\n\n                                   1            I agree to familiarize myself with, and abide by, the Local Rules of this Court, especially\n\n                                   2   the Standards of Professional Conduct for attorneys and the Alternative Dispute Resolution Local\n\n                                   3   Rules. I declare under penalty of perjury that the foregoing is true and correct.\n\n                                   4   Dated:            1/12/2026                                         Sara Fuks\n                                                                                                     APPLICANT\n                                   5\n\n                                   6\n\n                                   7\n\n                                   8                                  ORDER GRANTING APPLICATION\n\n                                   9                            FOR ADMISSION OF ATTORNEY PRO HAC VICE\n\n                                  10\n\n                                  11            IT IS HEREBY ORDERED THAT the application of                    Sara Fuks            is\n\n                                  12   granted, subject to the terms and conditions of Civil L.R. 11-3. All papers filed by the attorney\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13   must indicate appearance pro hac vice. Service of papers upon, and communication with, local co-\n\n                                  14   counsel designated in the application will constitute notice to the party.\n\n                                  15   Dated: January 12, 2026\n\n                                  16\n\n                                  17\n                                                                                  EUMI K. LEE\n                                  18                                              UNITED STATES DISTRICT JUDGE\n                                  19\n\n                                  20\n\n                                  21\n\n                                  22\n\n                                  23\n\n                                  24\n\n                                  25\n\n                                  26\n                                  27\n\n                                  28\n                                       Updated 11/2021                                   2\n\f","ocr_status":2,"date_upload":"2026-05-14T23:33:35.629394-07:00","document_number":"94","attachment_number":null,"pacer_doc_id":"035026634645","is_available":true,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Order on Motion for Pro Hac Vice","acms_document_guid":""}],"date_created":"2026-01-12T16:03:44.475461-08:00","date_modified":"2026-01-27T00:03:51.470328-08:00","date_filed":"2026-01-12","time_filed":"15:43:34","entry_number":94,"recap_sequence_number":"2026-01-12.002","pacer_sequence_number":400,"description":"ORDER granting 93 Motion for Pro Hac Vice as to attorney Sara Fuks. Signed by Judge Eumi K. Lee. (lrt, COURT STAFF) (Filed on 1/12/2026) (Entered: 01/12/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/450036497/","id":450036497,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/464844239/","id":464844239,"tags":[],"absolute_url":"/docket/70274365/93/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2026-01-12T12:03:47.280051-08:00","date_modified":"2026-01-27T00:03:51.442540-08:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"93","attachment_number":null,"pacer_doc_id":"035026632484","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Pro Hac Vice","acms_document_guid":""}],"date_created":"2026-01-12T12:03:47.242477-08:00","date_modified":"2026-01-27T00:03:51.412777-08:00","date_filed":"2026-01-12","time_filed":"11:32:21","entry_number":93,"recap_sequence_number":"2026-01-12.001","pacer_sequence_number":396,"description":"MOTION for leave to appear in Pro Hac Vice ( Filing fee $ 328, receipt number ACANDC-21531692.) filed by Tony Djie, Lindy Merrill. (Attachments: # 1 Exhibit 1 - NYS Certificate of Good Standing)(Fuks, Sara) (Filed on 1/12/2026) (Entered: 01/12/2026)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/447303521/","id":447303521,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/462052213/","id":462052213,"tags":[],"absolute_url":"/docket/70274365/92/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2025-12-15T17:33:55.845481-08:00","date_modified":"2026-01-27T00:03:51.384027-08:00","sha1":"f4839edc6e1c42961e8ff70fcc25044464548546","page_count":11,"file_size":142006,"filepath_local":"recap/gov.uscourts.cand.449628/gov.uscourts.cand.449628.92.0.pdf","filepath_ia":"https://archive.org/download/gov.uscourts.cand.449628/gov.uscourts.cand.449628.92.0.pdf","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"                                           Case 5:25-cv-04177-EKL        Document 92       Filed 12/15/25      Page 1 of 11\n\n\n\n\n                                   1\n\n                                   2\n\n                                   3\n\n                                   4                                   UNITED STATES DISTRICT COURT\n\n                                   5                                  NORTHERN DISTRICT OF CALIFORNIA\n\n                                   6\n\n                                   7        KARTHIK TRICHUR SUNDARAM,                      Case No. 25-cv-04177-EKL\n                                                         Plaintiff,\n                                   8\n                                                  v.\n                                   9\n\n                                  10        IOVANCE BIOTHERAPEUTICS, INC., et\n                                            al.,\n                                  11                     Defendants.\n                                  12\nNorthern District of California\n\n\n\n\n                                            DIMITRY FARBEROV,\n United States District Court\n\n\n\n\n                                                                                          Case No. 25-cv-04199-EKL\n                                  13\n                                                         Plaintiff,\n                                                                                          ORDER CONSOLIDATING CASES,\n                                  14                                                      APPOINTING LEAD PLAINTIFF AND\n                                                  v.\n                                                                                          LEAD COUNSEL, AND DENYING\n                                  15                                                      STIPULATION FOR APPOINTMENT OF\n                                            IOVANCE BIOTHERAPEUTICS, INC., et\n                                            al.,                                          CO-LEAD PLAINTIFFS AND CO-LEAD\n                                  16                                                      COUNSEL\n                                                      Defendants.\n                                  17\n\n                                  18            Before the Court are various motions to consolidate the two above-captioned cases, to\n                                  19   appoint lead plaintiff and lead counsel, and a stipulation to appoint co-lead plaintiffs and co-lead\n                                  20   counsel.1 For the following reasons, the Court hereby consolidates the cases, denies the\n                                  21   stipulation to appoint co-lead plaintiffs and co-lead counsel, and appoints the Merrill & Djie\n                                  22   Group as lead plaintiff. The Court also appoints Rosen Law as lead counsel and Schall Law as\n                                  23   additional counsel.\n                                  24   I.       BACKGROUND\n                                  25            These cases allege that Defendant Iovance Biotherapeutics, Inc. (\u201cIovance\u201d) and certain of\n                                  26   the company\u2019s executives misled investors in violation of Sections 10(b) and 20(a) of the\n                                  27\n                                       1\n                                  28    The Court finds this matter appropriate for resolution without oral argument pursuant to Civil\n                                       Local Rule 7-1(b).\n\f                                           Case 5:25-cv-04177-EKL         Document 92        Filed 12/15/25       Page 2 of 11\n\n\n\n\n                                   1   Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder. Both cases were filed\n\n                                   2   on May 15, 2025; Sundaram v. Iovance Biotherapeutics, Inc., No. 25-cv-04177-EKL, was\n\n                                   3   assigned the lower case number, thus becoming the lead case for purposes of this Order.2 On May\n\n                                   4   15, 2025, notice of the Sundaram action was published via GlobeNewswire. See ECF No. 46-4.3\n\n                                   5   Notice of the Farberov action was published via BusinessWire the following day. Farberov, No.\n\n                                   6   25-cv-04199-EKL, ECF No. 4. The notices alerted members of the putative class to the pending\n\n                                   7   actions and instructed that any request to be appointed lead plaintiff must be filed within 60 days\n\n                                   8   of the notice, or July 14 and July 15, respectively. On July 14, 2025, ten putative plaintiffs timely\n\n                                   9   filed motions to be appointed lead plaintiff and to appoint lead counsel. See ECF Nos. 15, 18, 21,\n\n                                  10   24, 28, 30, 35, 39, 45, 46.4 Since the initial motions were filed, seven movants have either withdrawn\n\n                                  11   their request to be appointed lead plaintiff or otherwise filed notices of non-opposition to another\n\n                                  12   movant being appointed lead plaintiff. See ECF Nos. 55, 63, 64, 65, 66, 72, 88.\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13            The remaining movants seeking to be appointed lead plaintiff are: the Merrill & Djie\n\n                                  14   Group with an estimated combined loss of $5,199,667, Not. of Errata at 2, ECF No. 56\n\n                                  15   (\u201cErrata\u201d);5 Westfall with an estimated loss of $1,264,855, Westfall Mot. at 3, ECF No. 46 (citing\n\n                                  16   Pafiti Decl. Ex. A, ECF No. 47-1);6 and the Iovance Investor Group with an estimated loss of\n\n                                  17   $1,198,550, ECF No. 35 at 7 (citing Linehan Decl. Ex. C, ECF No. 36-3).\n\n                                  18\n                                  19\n\n                                  20\n\n                                  21   2\n                                        The two cases were related, and Farberov v. Iovance Biotherapeutics, Inc., No. 25-cv-04199-\n                                  22   EKL, was reassigned to this Court on May 28, 2025. See Farberov ECF Nos. 8-9.\n                                       3\n                                         Unless otherwise specified, ECF citations refer to the docket in Sundaram v. Iovance\n                                  23   Biotherapeutics, Inc., No. 25-cv-04177-EKL.\n                                       4\n                                  24     Eight out of ten of the motions also included a request to consolidate the two above captioned\n                                       cases. See ECF Nos. 15, 18, 24, 30, 35, 39, 45, 46. The remaining two motions took no position on\n                                  25   consolidation. See ECF Nos. 21, 28.\n                                       5\n                                         While briefing on the motions to appoint lead plaintiff was still open, the Merrill & Djie Group\n                                  26   revised their loss chart and updated their estimated loss from $5,622,539 to $5,199,667. Errata at\n                                       2.\n                                  27   6\n                                         Competing movants challenge Westfall\u2019s loss calculation, but the Court need not reach this issue\n                                  28   because, as discussed below, the Merrill & Djie Group has the largest financial loss regardless of\n                                       the proper accounting of Westfall\u2019s loss.\n                                                                                          2\n\f                                        Case 5:25-cv-04177-EKL            Document 92          Filed 12/15/25     Page 3 of 11\n\n\n\n\n                                   1   II.     LEGAL STANDARD\n\n                                   2           A.      Consolidation of the Actions\n\n                                   3           Consolidation of securities class actions is appropriate under Federal Rule of Civil\n\n                                   4   Procedure 42(a) when the \u201cactions before the court involve a common question of law or fact.\u201d\n\n                                   5   See also 15 U.S.C. \u00a7 78u-4(a)(3)(B)(ii) (contemplating consolidation of securities actions).\n\n                                   6           B.      Lead Plaintiff\n\n                                   7           Under the PSLRA, it is the Court\u2019s responsibility to \u201cappoint the most adequate plaintiff as\n\n                                   8   lead plaintiff for the consolidated actions.\u201d Id. The Ninth Circuit has established a three-step\n\n                                   9   process for appointing a lead plaintiff. See In re Cavanaugh, 306 F.3d 726, 729-31 (9th Cir.\n\n                                  10   2002); In re Mersho, 6 F.4th 891, 899 (9th Cir. 2021).\n\n                                  11           At step one, the Court must determine whether \u201cnotice of the action [was] posted so\n\n                                  12   purported class members can move for lead plaintiff appointment.\u201d In re Mersho, 6 F.4th at 899\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13   (citing 15 U.S.C. \u00a7 78u-4(a)(3)(A)(i)(I)-(II)).\n\n                                  14           At step two, the Court must determine \u201cwhich movant is the \u2018most adequate plaintiff[.]\u2019\u201d\n\n                                  15   Id. There is a rebuttable presumption that the \u201cmost adequate plaintiff\u201d to lead a securities class\n\n                                  16   action is the person or group of persons that: (a) \u201chas either filed the complaint or made a motion\n\n                                  17   [for appointment as lead plaintiff]\u201d; (b) \u201chas the largest financial interest in the relief sought by the\n\n                                  18   class\u201d; and (c) \u201cotherwise satisfies the requirements of Rule 23 of the Federal Rules of Civil\n\n                                  19   Procedure.\u201d 15 U.S.C. \u00a7 78u-4(a)(3)(B)(iii). The statute allows a \u201cgroup of persons\u201d to be\n\n                                  20   appointed as lead plaintiff. In re Mersho, 6 F.4th at 899 (citing 15 U.S.C. \u00a7 78u-4(a)(3)(A)(iii)(I)).\n\n                                  21           At step three, the Court must determine whether another member of the purported plaintiff\n\n                                  22   class has rebutted \u201cthe presumptive lead plaintiff\u2019s showing that it satisfies Rule 23.\u201d Pampena v.\n\n                                  23   Musk, No. 22-CV-05937-CRB, 2023 WL 3082341, at *2 (N.D. Cal. Apr. 24, 2023) (citing In re\n\n                                  24   Cavanaugh, 306 F.3d at 730); see also In re Mersho, 6 F.4th at 899. Rebutting the presumption\n\n                                  25   \u201ccan be done using proof that the presumptive lead plaintiff (1) will not fairly and adequately\n\n                                  26   protect the interests of the class, or (2) is subject to unique defenses that render the plaintiff\n\n                                  27   incapable of adequately representing the class.\u201d Pampena, 2023 WL 3082341 at *2 (citing Fed.\n\n                                  28   R. Civ. P. 23(a); 15 U.S.C. \u00a7 78u-4(a)(3)(B)(iii)(II)). \u201c[J]ust because \u2018the presumption is\n                                                                                           3\n\f                                           Case 5:25-cv-04177-EKL        Document 92          Filed 12/15/25    Page 4 of 11\n\n\n\n\n                                   1   rebuttable does not mean that it may be set aside for any reason that the court may deem\n\n                                   2   sufficient.\u2019 The statute requires proof that the presumptive lead plaintiff is not adequate.\u201d In re\n\n                                   3   Mersho, 6 F.4th at 899 (internal citation omitted). \u201cIf the presumption is not rebutted, the\n\n                                   4   presumptively most adequate plaintiff must be selected as lead plaintiff.\u201d Id.\n\n                                   5   III.     DISCUSSION\n\n                                   6            The Court first addresses consolidation of the actions and then appointment of lead\n\n                                   7   plaintiff and lead counsel.\n\n                                   8            A.     Consolidation of the Actions\n\n                                   9            Consolidation of the Sundaram and Farberov actions is appropriate because the actions\n\n                                  10   involve common questions of law and fact. See Fed. R. Civ. P. 42(a). Specifically, both actions\n\n                                  11   allege substantially the same securities violations arising from Defendants\u2019 purported statements\n\n                                  12   to investors. In fact, eight of the ten movants for lead plaintiff also moved to consolidate the\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13   Sundaram and Farberov actions. Thus, these actions shall be consolidated.\n\n                                  14            B.     Appointment of Lead Plaintiff7\n\n                                  15                   1.      The remaining movants stipulate to appoint co-lead plaintiffs\n\n                                  16            Following the close of briefing on the motions to appoint lead plaintiff, the remaining\n\n                                  17   movants \u2013 the Merrill & Djie Group, Westfall, and the Iovance Investor Group \u2013 submitted a\n\n                                  18   stipulation for the Merrill & Djie Group and Westfall to be appointed co-lead plaintiff and for their\n\n                                  19   respective counsel to be appointed co-lead counsel. ECF No. 88 (\u201cStip.\u201d). The movants represent\n\n                                  20   that they believe \u201cit is in the best interest of the Class to amicably resolve the motions and pool\n\n                                  21   their resources to effectively and efficiently prosecute the Related Actions.\u201d Id. at 5. The Merrill\n\n                                  22   & Djie Group and Westfall also represent that they have \u201creviewed one another\u2019s submissions to\n\n                                  23   the Court\u201d and \u201cbelieve that they each satisfy the typicality and adequacy requirements of Rule\n\n                                  24   23.\u201d Id. at 4. However, prior to the stipulation, Westfall and the Iovance Investor Group\n\n                                  25   adamantly opposed the Merrill & Djie Group\u2019s appointment as lead plaintiff on the basis that the\n\n                                  26\n                                  27   7\n                                         Notice of the action was posted pursuant to 15 U.S.C. \u00a7 78u-4(a)(3)(A)(i)(I)-(II) and all movants\n                                  28   timely filed their respective motions to be appointed lead plaintiff.\n\n                                                                                          4\n\f                                           Case 5:25-cv-04177-EKL        Document 92           Filed 12/15/25     Page 5 of 11\n\n\n\n\n                                   1   Group had allegedly committed multiple disqualifying errors in its motion. They specifically\n\n                                   2   \u201ccall[ed] into question [the Merrill & Djie Group\u2019s] ability to adequately represent the Class[.]\u201d\n\n                                   3   Iovance Investor Group Reply at 1, ECF No. 77 (\u201cIovance Group Reply\u201d). The stipulation does\n\n                                   4   not address these concerns.\n\n                                   5            Therefore, because the Court has an independent obligation to identify and appoint the\n\n                                   6   most adequate lead plaintiff, the Court DENIES the stipulation and proceeds to evaluate the\n\n                                   7   competing motions under the three-step process outlined in In re Mersho.\n\n                                   8                   2.      The Merrill & Djie Group is the presumptive lead plaintiff\n\n                                   9            The Court finds that the Merrill & Djie Group is presumptively the most adequate lead\n\n                                  10   plaintiff. The Merrill & Djie group has the largest financial interest in the litigation. Courts assess\n\n                                  11   financial interest according to several factors \u2013 the number of shares purchased, the amount of\n\n                                  12   funds expended, and the monetary loss suffered. See, e.g., In re Diamond Foods, Inc., Sec. Litig.,\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13   281 F.R.D. 405, 408 (N.D. Cal. 2012). Monetary loss is generally considered the most significant\n\n                                  14   factor. Id. The remaining movants do not dispute that the Merrill & Djie Group has the largest\n\n                                  15   financial interest with an estimated loss of $5,199,667.8\n\n                                  16            In addition, the Merrill & Djie Group has made a prima facie showing that it satisfies Rule\n\n                                  17   23\u2019s typicality and adequacy requirements. See Hessefort v. Super Micro Comput., Inc., 317 F.\n\n                                  18   Supp. 3d 1056, 1060-61 (N.D. Cal. 2018) (\u201cOnce a movant has demonstrated that it has the largest\n\n                                  19   financial interest, it need only make a prima facie showing of its typicality and adequacy.\u201d). As to\n\n                                  20   typicality, the Merrill & Djie Group\u2019s claims are typical of the putative class because its members\n\n                                  21   allegedly acquired Iovance securities at artificially inflated prices due to Defendants\u2019 alleged\n\n                                  22   misrepresentations, which are the same allegations across the putative class. See Merrill & Djie\n\n                                  23   Mot. at 8, ECF No. 24 (\u201cM&D Mot.\u201d). As to adequacy, the Merrill & Djie Group has a\n\n                                  24   substantial interest in recovering its claimed losses, so its interests are aligned with the interests of\n\n                                  25   the putative class. Accordingly, the presumption that the Merrill & Djie Group is the most\n\n                                  26\n                                       8\n                                  27    Instead, movants Iovance Investor Group and Westfall argue that the Merrill & Djie Group\n                                       should be disqualified from consideration under the third requirement \u2013 Rule 23 adequacy. See\n                                  28   Westfall Reply at 6, ECF No. 80; Iovance Investor Group Reply at 1-2.\n\n                                                                                           5\n\f                                        Case 5:25-cv-04177-EKL           Document 92          Filed 12/15/25    Page 6 of 11\n\n\n\n\n                                   1   adequate plaintiff has been satisfied. The burden therefore shifts to the remaining movants to\n\n                                   2   rebut that presumption. See In re Mersho, 6 F.4th at 899.\n\n                                   3                  3.      Competing movants fail to rebut the presumption\n\n                                   4          The competing movants, the Iovance Investor Group and Westfall, argue that the Merrill &\n\n                                   5   Djie Group should be disqualified from lead plaintiff consideration because it is \u201cinadequate\n\n                                   6   within the meaning of Rule 23.\u201d Westfall Reply at 2-3; see also Westfall Opp. at 4, ECF No. 67;\n\n                                   7   Iovance Group Reply at 2-3. The Court finds that the competing movants have not pointed to\n\n                                   8   \u201cevidence of inadequacy\u201d sufficient to rebut the presumption.\n\n                                   9          Lack of cohesion: The competing movants argue that the Merrill & Djie Group should be\n\n                                  10   disqualified because it has \u201cfailed to demonstrate that it is a cohesive group, capable of adequately\n\n                                  11   representing the class.\u201d Iovance Group Reply at 1. Both argue that the representations made in\n\n                                  12   the Merrill & Djie Group\u2019s motion are inadequate because the motion did not make \u201cany\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13   attestations that they understand the responsibilities of a lead plaintiff and are ready to undertake\n\n                                  14   those responsibilities on the Class\u2019s behalf.\u201d Iovance Group Reply at 2; Westfall Opp. at 9-10.\n\n                                  15   They further argue that the joint attestation submitted with the Merrill & Djie Group\u2019s opposition\n\n                                  16   is untimely and should not be considered. The Court disagrees.\n\n                                  17          The Court is satisfied that the Merrill & Djie Group is cohesive and capable of adequately\n\n                                  18   representing the class. The group is very small, consisting of only two individuals that are\n\n                                  19   \u201csophisticated investors\u201d and businesspeople with \u201cample experience overseeing counsel.\u201d M&D\n\n                                  20   Mot. at 8-9; see also In re Mersho, 6 F.4th at 902 (explaining that \u201ccourts often consider . . . the\n\n                                  21   size of the group\u201d in assessing adequacy); In re Network Assocs., Inc., Sec. Litig., 76 F. Supp. 2d\n\n                                  22   1017, 1053 (N.D. Cal. 1999) (explaining that courts sometimes refuse \u201cto appoint large, random\n\n                                  23   assemblages of unrelated persons as lead plaintiff\u201d). The Merrill & Djie Group\u2019s motion explains\n\n                                  24   that they \u201cdesire to prosecute this action on behalf of the Class\u201d and that they are \u201caware of their\n\n                                  25   joint responsibility to the class as Co-Lead Plaintiffs.\u201d M&D Mot. at 8-9. It further states that\n\n                                  26   they are not aware of any unique defenses that could be raised against them and explains that\n\n                                  27   Merrill and Djie, \u201camong other things, were introduced to each other, established and used a\n\n                                  28   dedicated case-related chat protocol for their lead plaintiff motion and this case, and agreed to\n                                                                                          6\n\f                                           Case 5:25-cv-04177-EKL         Document 92        Filed 12/15/25      Page 7 of 11\n\n\n\n\n                                   1   move as Co-Lead Plaintiffs.\u201d Id. Based on these statements, Merrill & Djie Group has\n\n                                   2   demonstrated its cohesiveness and willingness and ability to adequately represent the interests of\n\n                                   3   the class. The competing movants have not produced evidence that \u201ccast[s] genuine and serious\n\n                                   4   doubt on [the] plaintiff\u2019s willingness or ability to perform the functions of lead plaintiff.\u201d In re\n\n                                   5   Mersho, 6 F.4th at 901 (citation omitted) (\u201cCompeting movants must convince the district court\n\n                                   6   that the presumptive lead plaintiff would not be adequate, not merely that the district court was\n\n                                   7   wrong in determining that the prima facie elements of adequacy were met. That is the purpose of\n\n                                   8   the presumption and burden-shifting.\u201d).9\n\n                                   9            Improper movant group: Westfall argues that the Merrill & Djie Group in an improper\n\n                                  10   movant group that was \u201chastily cobbled together by their attorneys for the sole purpose of securing\n\n                                  11   the PSLRA\u2019s largest financial interest.\u201d Westfall Reply at 8. This argument fails for three\n\n                                  12   reasons.\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13            First, the statute expressly allows a \u201cgroup of persons\u201d to be appointed as lead plaintiff, so\n\n                                  14   the fact that the Merrill & Djie Group consists of two individuals does not disqualify it. In re\n\n                                  15   Mersho, 6 F.4th at 899 (citing 15 U.S.C. \u00a7 78u-4(a)(3)(A)(iii)(I)). Second, the fact that Merrill\n\n                                  16   and Djie may not have known each other prior to this litigation does not disqualify their group\n\n                                  17   from appointment as lead plaintiff. See id. at 902 (explaining that the proper test is \u201cwhether [the]\n\n                                  18   group would \u2018fairly and adequately represent the interests of the class\u2019\u201d not whether the individual\n\n                                  19   members have a pre-litigation relationship); Bruce v. Suntech Power Holdings Co., No. CV 12-\n\n                                  20   04061 RS, 2012 WL 5927985, at *2 (N.D. Cal. Nov. 13, 2012) (\u201cWhile a pre-litigation\n\n                                  21   relationship amongst lead plaintiffs is preferred, it is not required.\u201d). Third, the Merrill & Djie\n\n                                  22   Group did not need to \u201ccobble together\u201d individual plaintiffs to satisfy the largest financial interest\n\n                                  23   requirement because Merrill independently meets that requirement with an estimated loss of\n\n                                  24\n\n                                  25\n                                       9\n                                         Moreover, Merrill and Djie\u2019s joint declaration submitted with their opposition brief reaffirms\n                                       their ability to serve as lead plaintiff and provides additional information detailing their\n                                  26   understanding of their obligation to oversee counsel and their fiduciary duty to the entire class.\n                                       Merrill & Djie Joint Decl. at 1-2, ECF No. 69-1. The Court finds this joint declaration timely\n                                  27   because it primarily reaffirms the statements made in their original motion and because \u201c[b]riefing\n                                       on the motion was ongoing, and the other groups had the opportunity to address the joint\n                                  28   declaration in their replies.\u201d Robb v. Fitbit Inc., No. 16-CV-00151-SI, 2016 WL 2654351, at *4\n                                       n.7 (N.D. Cal. May 10, 2016).\n                                                                                           7\n\f                                        Case 5:25-cv-04177-EKL            Document 92         Filed 12/15/25     Page 8 of 11\n\n\n\n\n                                   1   $3,167,674.50. Errata Ex. A at 3, ECF No. 56-1; see also Bruce, 2012 WL 5927985, at *2 (\u201cThis\n\n                                   2   is not a case, however, in which lawyers aggregated plaintiffs in order to overcome the largest\n\n                                   3   stake requirement. Rather, [individual member of movant group] meets that requirement on his\n\n                                   4   own.\u201d).\n\n                                   5             Errors in original loss calculation: Finally, the competing movants argue that the Merrill\n\n                                   6   & Djie Group should be disqualified because the loss calculation submitted with its original\n\n                                   7   motion contained errors. See Errata at 2 (revising estimated loss from $5,622,539 to $5,199,667).\n\n                                   8   \u201cAn error in claimed losses may render a movant inadequate if there is \u2018evidence of bad faith or\n\n                                   9   intent to deceive the court or the parties.\u2019\u201d In re Apple Inc. Sec. Litig., No. 4:19-CV-2033-YGR,\n\n                                  10   2022 WL 354785, at *5 (N.D. Cal. Feb. 4, 2022) (quoting In re SLM Corp. Sec. Litig., No.08-cv-\n\n                                  11   1029 (WHP), 2012 WL 209095, at *8 (S.D.N.Y. Jan. 24, 2012)). Competing movants do not\n\n                                  12   make such a showing here because the group corrected its loss calculation within one week of\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13   filing its original motion. Id. (finding no bad faith or intent to deceive where the plaintiff\n\n                                  14   \u201ccorrected its inadvertent errors on the certification (albeit two years after the fact)\u201d); Pampena,\n\n                                  15   2023 WL 3082341, at *3 (\u201cMoreover, because [individual] promptly fixed this seemingly clerical\n\n                                  16   error by submitting a supplemental certification, his mistake is not grounds for finding the Group\n\n                                  17   inadequate under Rule 23.\u201d). Finally, this type of inadvertent error is \u201cnot the type[] of error[] that\n\n                                  18   would normally preclude a finding of adequacy to represent the class.\u201d In re Apple Inc. Sec. Litig.,\n\n                                  19   2022 WL 354785, at *5 (\u201cNor is a computational error the type of credibility issue that would\n\n                                  20   \u2018divert the fact finders\u2019 attention from the merits and thus infect the claims of the class as a\n\n                                  21   whole.\u2019\u201d (citation omitted)).\n\n                                  22                                                          ***\n\n                                  23             In sum, the competing movants have not provided sufficient evidence to rebut the statutory\n\n                                  24   presumption that the Merrill & Djie Group is the most adequate plaintiff. Therefore, the motion to\n\n                                  25   appoint the Merrill & Djie Group as lead plaintiff is GRANTED.\n\n                                  26             C.     Appointment of Lead Counsel\n\n                                  27             The Merrill & Djie Group\u2019s choice of Rosen Law as Lead Counsel and Schall Law as\n\n                                  28   Additional Counsel is reasonable. See 15 U.S.C. \u00a7 78u-4(a)(3)(B)(v); Cohen v. U.S. Dist. Court,\n                                                                                          8\n\f                                        Case 5:25-cv-04177-EKL            Document 92         Filed 12/15/25    Page 9 of 11\n\n\n\n\n                                   1   586 F.3d 703, 712 (9th Cir. 2009) (holding that if the lead plaintiff makes a \u201creasonable choice of\n\n                                   2   counsel, the district court should generally defer to that choice\u201d). Movants represent that \u201c[t]he\n\n                                   3   firms have been actively researching the claims of Movants and the putative class, reviewing\n\n                                   4   publicly available financial and other documents and gathering information in support of the\n\n                                   5   claims against the Defendants\u201d and that \u201cthe firms are experienced in the area of securities\n\n                                   6   litigation and class actions, having been appointed as lead counsel in securities class actions in this\n\n                                   7   District and in numerous courts throughout the nation.\u201d M&D Mot. at 9. In addition, according to\n\n                                   8   Rosen Law\u2019s resume, the firm has served as lead or co-lead counsel in numerous securities class\n\n                                   9   actions and has recovered billions of dollars serving as lead or co-lead counsel. Rosen Decl. Ex. 5\n\n                                  10   at 11-22, ECF No. 25-5. Based on these representations, Rosen Law is qualified to serve as lead\n\n                                  11   counsel and Schall Law is qualified to serve as additional counsel. Accordingly, the motion to\n\n                                  12   appoint Rosen Law as lead counsel and Schall Law as additional counsel is GRANTED.\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13   IV.    CONCLUSION\n\n                                  14          For the foregoing reasons, the Court ORDERS as follows:\n\n                                  15          1.      Pursuant to Federal Rule of Civil Procedure 42(a), the above-captioned related\n\n                                  16   actions are hereby consolidated for all purposes into one action.\n\n                                  17          2.      Within thirty days, the parties shall meet and confer and propose a schedule for the\n\n                                  18   filing of a consolidated or amended complaint and Defendants\u2019 responsive pleading. Order\n\n                                  19   Granting Stip. at 3, ECF No. 73.\n\n                                  20          3.      This Order shall apply to the above-captioned action (the \u201cAction\u201d) and to each\n\n                                  21   case that relates to the same subject matter that is subsequently filed in or transferred to this Court\n\n                                  22   and consolidated with the Action.\n\n                                  23          4.      A Master File is established for this proceeding. The Master File shall be Civil\n\n                                  24   Action No. 25-cv-04177-EKL. The Clerk shall file all pleadings in the Master File and note such\n\n                                  25   filings on the Master Docket. Every pleading in the Action shall have the following caption: In re\n\n                                  26   Iovance Biotherapeutics, Inc. Securities Litigation, No. 25-cv-04177-EKL (N.D. Cal.).\n\n                                  27\n\n                                  28\n                                                                                          9\n\f                                       Case 5:25-cv-04177-EKL           Document 92         Filed 12/15/25      Page 10 of 11\n\n\n\n\n                                   1          5.      Whenever a case that should be consolidated into this Action is filed in, or\n\n                                   2   transferred to, this District, the parties to the Action shall file an administrative motion to consider\n\n                                   3   whether that case should be related pursuant to Civil L.R. 3-12.\n\n                                   4          6.      All related actions that are subsequently filed in, or transferred to, this District shall\n\n                                   5   be consolidated into this Action for pretrial purposes. A party in a related action that objects to\n\n                                   6   such consolidation, or to any other provision of this Order, must file an application for relief from\n\n                                   7   this Order within ten (10) days after the action is related. Nothing in the foregoing shall be\n\n                                   8   construed as a waiver of Defendants\u2019 right to object to the consolidation of any subsequently-filed\n\n                                   9   or transferred related action.\n\n                                  10          7.      The stipulation to appoint co-lead plaintiffs and co-lead counsel, ECF No. 88, is\n\n                                  11   DENIED.\n\n                                  12          8.      The Merrill & Djie Group\u2019s motion for appointment as co-lead counsel and for\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13   approval of counsel, ECF No. 24, is GRANTED. All other motions for appointment of lead\n\n                                  14   plaintiff and lead counsel are DENIED.\n\n                                  15          9.       Plaintiffs Lindy Merrill and Tony Djie of the Merrill & Djie Group are appointed\n\n                                  16   to serve as Lead Plaintiff in the Action pursuant to 15 U.S.C. \u00a7 78u-4(a)(3)(B).\n\n                                  17          10.     The Merrill & Djie Group\u2019s selection of Rosen Law as Lead Counsel for the\n\n                                  18   putative class is approved pursuant to 15 U.S.C. \u00a7 78u-4(a)(3)(B)(v). Lead Counsel shall have the\n\n                                  19   authority to speak for all Plaintiffs and putative class members in all matters regarding the\n\n                                  20   litigation, including, but not limited to, pretrial proceedings, motion practice, trial, and settlement.\n\n                                  21   Lead Counsel shall make all work assignments in such a manner as to facilitate the orderly and\n\n                                  22   efficient prosecution of this litigation, and to avoid duplicative or unproductive effort.\n\n                                  23   Additionally, Lead Counsel shall have the following responsibilities:\n\n                                  24                  a. to brief and argue motions;\n\n                                  25                  b. to initiate and conduct discovery, including, but not limited to, coordination of\n\n                                  26                      discovery with Defendants\u2019 counsel, and the preparation of written\n\n                                  27                      interrogatories, requests for admissions, and requests for production of\n\n                                  28                      documents;\n                                                                                          10\n\f                                       Case 5:25-cv-04177-EKL           Document 92        Filed 12/15/25      Page 11 of 11\n\n\n\n\n                                   1                  c. to direct and coordinate the examination of witnesses in depositions;\n\n                                   2                  d. to act as spokesperson at pretrial conferences;\n\n                                   3                  e. to call and chair meetings of Plaintiffs\u2019 counsel as appropriate or necessary\n\n                                   4                      from time to time;\n\n                                   5                  f. to initiate and conduct any settlement negotiations with Defendants\u2019 counsel;\n\n                                   6                  g. to provide general coordination of the activities of Plaintiffs\u2019 counsel and to\n\n                                   7                      delegate work responsibilities to selected counsel as may be required, in such a\n\n                                   8                      manner as to lead to the orderly and efficient prosecution of this litigation and\n\n                                   9                      to avoid duplication or unproductive effort;\n\n                                  10                  h. to consult with and employ experts;\n\n                                  11                  i. to receive and review periodic time reports of all attorneys on behalf of\n\n                                  12                      Plaintiffs, to determine if the time is being spent appropriately and for the\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13                      benefit of Plaintiffs, and to determine and distribute Plaintiffs\u2019 attorneys\u2019 fees;\n\n                                  14                      and\n\n                                  15                  j. to perform such other duties as may be expressly authorized by further order of\n\n                                  16                      this Court.\n\n                                  17          11.     The Merrill & Djie Group\u2019s selection of Schall Law as additional counsel for the\n\n                                  18   putative class in the Action is approved.\n\n                                  19          12.     Westfall\u2019s administrative motion to for leave to file a sur-reply, ECF No. 81, is\n\n                                  20   TERMINATED AS MOOT because the Court need not reach the arguments addressed therein to\n\n                                  21   resolve the motions to appoint lead plaintiff.\n\n                                  22          This Order terminates ECF Nos. 15, 18, 21, 24, 28, 30, 35, 39, 45, 46, 81, 88.\n\n                                  23          IT IS SO ORDERED.\n\n                                  24   Dated: December 15, 2025\n\n                                  25\n\n                                  26\n                                                                                                     Eumi K. Lee\n                                  27                                                                 United States District Judge\n                                  28\n                                                                                         11\n\f","ocr_status":2,"date_upload":"2026-01-05T16:37:38.242050-08:00","document_number":"92","attachment_number":null,"pacer_doc_id":"035026547639","is_available":true,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Order AND ~Util - Terminate Motions","acms_document_guid":""}],"date_created":"2025-12-15T17:33:55.830195-08:00","date_modified":"2026-01-27T00:03:51.352959-08:00","date_filed":"2025-12-15","time_filed":"17:25:43","entry_number":92,"recap_sequence_number":"2025-12-15.001","pacer_sequence_number":371,"description":"ORDER CONSOLIDATING CASES, APPOINTING LEAD PLAINTIFF AND LEAD COUNSEL, AND DENYING STIPULATION FOR APPOINTMENT OF CO-LEAD PLAINTIFFS AND CO-LEAD COUNSEL. The Master File shall be Civil Action No. 25-cv-04177-EKL. Every pleading in the Action shall have the following caption: In re Iovance Biotherapeutics, Inc. Securities Litigation, No. 25-cv-04177-EKL (N.D. Cal.). Plaintiffs Lindy Merrill and Tony Djie of the Merrill & Djie Group are appointed to serve as Lead Plaintiff. The Merrill & Djie Groups selection of Rosen Law as Lead Counsel for the putative class is approved. Signed by Judge Eumi K. Lee on 12/15/2025. (lrt, COURT STAFF) (Filed on 12/15/2025) (Entered: 12/15/2025)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/445938945/","id":445938945,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/460650453/","id":460650453,"tags":[],"absolute_url":"/docket/70274365/91/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2025-12-02T16:34:12.058859-08:00","date_modified":"2026-05-18T05:35:06.999174-07:00","sha1":"3e16935626a37f4404b50b38133a724e5c07add7","page_count":2,"file_size":214538,"filepath_local":"recap/gov.uscourts.cand.449628/gov.uscourts.cand.449628.91.0.pdf","filepath_ia":"https://archive.org/download/gov.uscourts.cand.449628/gov.uscourts.cand.449628.91.0.pdf","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"                                        Case 5:25-cv-04177-EKL            Document 91       Filed 12/02/25     Page 1 of 2\n\n\n\n\n                                   1                                    UNITED STATES DISTRICT COURT\n\n                                   2                                 NORTHERN DISTRICT OF CALIFORNIA\n\n                                   3\n\n                                   4          SUNDARAM, et al.                  ,           Case No. 5:25-cv-04177-EKL\n                                                        Plaintiff(s),\n                                   5\n                                                                                            APPLICATION FOR ADMISSION OF\n                                                  v.                                        ATTORNEY PRO HAC VICE\n                                   6\n                                                                                            (CIVIL LOCAL RULE 11-3)\n                                   7          IOVANCE BIOTHERAPEUT ,\n                                                        Defendant(s).\n                                   8\n\n                                   9\n\n                                  10          I, Veronica Callahan            , an active member in good standing of the bar of\n\n                                  11    the State of New York                 , hereby respectfully apply for admission to practice pro hac\n\n                                  12   vice in the Northern District of California representing: Defendants                         in the\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13   above-entitled action. My local co-counsel in this case is Tommy Huynh                       , an\n\n                                  14   attorney who is a member of the bar of this Court in good standing and who maintains an office\n\n                                  15                                                                     306222\n                                       within the State of California. Local co-counsel\u2019s bar number is: _________________.\n\n                                  16   \u0015\u0018\u0013\u0003:\u0003\u0018\u0018WK\u00036W\u0011\u000f\u00031HZ\u0003<RUN\u000f\u00031HZ\u0003<RUN\u000f\u0003                 \u0016\u0003(PEDUFDGHUR\u0003&WU\u00036WH\u0003\u0014\u0013\u000f\u00036DQ\u0003)UDQFLVFR\u000f\u0003&$\u0003\n                                       \u0014\u0013\u0013\u0014\u001c\u0010\u001c\u001a\u0014\u0013                                           \u001c\u0017\u0014\u0014\u0014\u0010\u0017\u0013\u0015\u0017\n                                  17    MY ADDRESS OF RECORD                                 LOCAL CO-COUNSEL\u2019S ADDRESS OF RECORD\n\n                                  18   (212) 836-8000                                       (415) 471-3147\n                                        MY TELEPHONE # OF RECORD                             LOCAL CO-COUNSEL\u2019S TELEPHONE # OF RECORD\n                                  19\n                                       veronica.callahan@arnoldporter.com                   tommy.huynh@arnoldporter.com\n                                  20    MY EMAIL ADDRESS OF RECORD                           LOCAL CO-COUNSEL\u2019S EMAIL ADDRESS OF RECORD\n\n                                  21\n\n                                  22          I am an active member in good standing of a United States Court or of the highest court of\n                                  23   another State or the District of Columbia, as indicated above; my bar number is: 2918126              .\n                                  24          A true and correct copy of a certificate of good standing or equivalent official document\n                                  25   from said bar is attached to this application.\n                                  26                                                                  zero\n                                              I have been granted pro hac vice admission by the Court _______ times in the 12 months\n                                  27   preceding this application.\n                                  28\n\f                                         Case 5:25-cv-04177-EKL            Document 91        Filed 12/02/25     Page 2 of 2\n\n\n\n\n                                   1            I agree to familiarize myself with, and abide by, the Local Rules of this Court, especially\n\n                                   2   the Standards of Professional Conduct for attorneys and the Alternative Dispute Resolution Local\n\n                                   3   Rules. I declare under penalty of perjury that the foregoing is true and correct.\n\n                                   4          \u0003    \u0003 2, 2025\n                                       Dated: December   \u0003             \u0003      \u0003       \u0003       \u0003\u0003\u0003\u0003\u0003\u0003\u0012V\u0012 Veronica Callahan\n                                                                                                        APPLICANT\n                                   5\n\n                                   6\n\n                                   7\n\n                                   8                                  ORDER GRANTING APPLICATION\n\n                                   9                          FOR ADMISSION OF ATTORNEY PRO HAC VICE\n\n                                  10\n\n                                  11            IT IS HEREBY ORDERED THAT the application of Veronica Callahan                       is\n\n                                  12   granted, subject to the terms and conditions of Civil L.R. 11-3. All papers filed by the attorney\nNorthern District of California\n United States District Court\n\n\n\n\n                                  13   must indicate appearance pro hac vice. Service of papers upon, and communication with, local co-\n\n                                  14   counsel designated in the application will constitute notice to the party.\n\n                                  15   Dated: December 2, 2025\n\n                                  16\n                                  17\n                                                                                  EUMI K. LEE\n                                  18                                              UNITED STATES DISTRICT JUDGE\n                                  19\n\n                                  20\n\n                                  21\n\n                                  22\n\n                                  23\n\n                                  24\n\n                                  25\n\n                                  26\n\n                                  27\n\n                                  28\n                                       Updated 11/2021                                    2\n\f","ocr_status":2,"date_upload":"2026-05-14T23:33:35.541310-07:00","document_number":"91","attachment_number":null,"pacer_doc_id":"035026497831","is_available":true,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Order on Motion for Pro Hac Vice","acms_document_guid":""}],"date_created":"2025-12-02T16:34:11.933702-08:00","date_modified":"2026-01-27T00:03:51.294334-08:00","date_filed":"2025-12-02","time_filed":"16:23:03","entry_number":91,"recap_sequence_number":"2025-12-02.002","pacer_sequence_number":368,"description":"ORDER granting 90 Motion for Pro Hac Vice as to attorney Veronica Callahan. Signed by Judge Eumi K. Lee. (lrt, COURT STAFF) (Filed on 12/2/2025) (Entered: 12/02/2025)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/445888404/","id":445888404,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/460599174/","id":460599174,"tags":[],"absolute_url":"/docket/70274365/90/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2025-12-02T12:08:13.533448-08:00","date_modified":"2026-01-27T00:03:51.270883-08:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"90","attachment_number":null,"pacer_doc_id":"035026495443","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Pro Hac Vice","acms_document_guid":""}],"date_created":"2025-12-02T12:08:13.445278-08:00","date_modified":"2026-01-27T00:03:51.242433-08:00","date_filed":"2025-12-02","time_filed":"11:52:49","entry_number":90,"recap_sequence_number":"2025-12-02.001","pacer_sequence_number":361,"description":"MOTION for leave to appear in Pro Hac Vice ( Filing fee $ 328, receipt number ACANDC-21405697.) filed by Jean-Marc Bellemin, Igor P. Bilinsky, Iovance Biotherapeutics, Inc., Daniel G. Kirby, Frederick G. Vogt. (Attachments: # 1 Exhibit - New York State Certificate of Good Standing)(Callahan, Veronica) (Filed on 12/2/2025) (Entered: 12/02/2025)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/438856997/","id":438856997,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/453369470/","id":453369470,"tags":[],"absolute_url":"","date_created":"2025-09-24T14:09:02.557221-07:00","date_modified":"2025-09-24T14:09:02.563933-07:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"","attachment_number":null,"pacer_doc_id":"","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Clerk's Notice","acms_document_guid":""}],"date_created":"2025-09-24T14:09:02.542762-07:00","date_modified":"2025-09-24T14:09:02.542773-07:00","date_filed":"2025-09-24","time_filed":"13:56:09","entry_number":null,"recap_sequence_number":"2025-09-24.001","pacer_sequence_number":null,"description":"","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/438367642/","id":438367642,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/452866402/","id":452866402,"tags":[],"absolute_url":"/docket/70274365/88/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2025-09-19T09:39:48.789527-07:00","date_modified":"2026-01-27T00:03:51.157418-08:00","sha1":"fc8a17aae44a573aff02e6c20da39cfa45008538","page_count":10,"file_size":426229,"filepath_local":"recap/gov.uscourts.cand.449628/gov.uscourts.cand.449628.88.0.pdf","filepath_ia":"https://archive.org/download/gov.uscourts.cand.449628/gov.uscourts.cand.449628.88.0.pdf","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"     Case 5:25-cv-04177-EKL        Document 88        Filed 09/19/25   Page 1 of 10\n\n\n\n\n     THE ROSEN LAW FIRM, P.A.\n 1   Laurence M. Rosen, Esq. (SBN 219683)\n 2   355 South Grand Avenue, Suite 2450\n     Los Angeles, CA 90071\n 3   Telephone: (213) 785-2610\n     Facsimile: (213) 226-4684\n 4   Email: lrosen@rosenlegal.com\n 5\n     Counsel for Lindy Merrill & Tony Djie and [Proposed]\n 6   Lead Counsel for Plaintiffs and the Class\n 7   [Additional counsel on signature page]\n 8\n 9                             UNITED STATES DISTRICT COURT\n                              NORTHERN DISTRICT OF CALIFORNIA\n10\n11     KARTHIK TRICHUR SUNDARAM,                  )     Case No. 5:25-cv-04177-EKL\n       Individually and on Behalf of All Others   )\n12     Similarly Situated,                        )     STIPULATION AND [PROPOSED]\n                                                  )     ORDER CONSOLIDATING\n13              Plaintiff,                        )     RELATED ACTIONS, APPOINTING\n14                                                )     CO-LEAD PLAINTIFFS, AND\n                v.                                )     APPROVING SELECTION OF CO-\n15                                                )     LEAD COUNSEL\n       IOVANCE BIOTHERAPEUTICS, INC.,             )\n16     FREDERICK G. VOGT, JEAN-MARC               )     CLASS ACTION\n17     BELLEMIN, IGOR P. BLINSKY, and             )\n       DANIEL G. KIRBY,                           )     Judge: Eumi K. Lee\n18                                                )     Hearing: October 1, 2025\n                Defendants.                       )     Time: 10:00 a.m.\n19                                                )     Courtroom: 7 \u2013 4th Floor\n                                                  )\n20\n                                                  )\n21                                                )\n\n22\n23\n24    [Additional caption on next page]\n25\n26\n27\n28\n                                                  1\n        STIPULATION AND [PROPOSED] ORDER CONSOLIDATING RELATED ACTIONS, APPOINTING\n       CO-LEAD PLAINTIFFS, AND APPROVING SELECTION OF CO-LEAD COUNSEL \u2013 Case No. 5:25-cv-\n                                          04177-EKL\n\f     Case 5:25-cv-04177-EKL         Document 88          Filed 09/19/25   Page 2 of 10\n\n\n\n\n       DIMITRY FARBEROV, Individually and                ) Case No. 5:25-cv-04199-EKL\n 1\n       on Behalf of All Others Similarly Situated,       )\n 2                                                       ) CLASS ACTION\n                Plaintiff,                               )\n 3                                                       ) Judge: Eumi K. Lee\n                v.                                       )\n 4                                                       )\n 5     IOVANCE BIOTHERAPEUTICS, INC.,                    )\n       FREDERICK G. VOGT, JEAN-MARC                      )\n 6     BELLEMIN, and IGOR P. BLINSKY,                    )\n                                                         )\n 7              Defendants.                              )\n 8                                                       )\n                                                         )\n 9\n10\n            Lead Plaintiff Movants Lindy Merrill and Tony Djie (collectively, the \u201cMerrill & Djie\n11\n     Group\u201d) and Anthony Westfall (\u201cWestfall\u201d), by and through their undersigned counsel, hereby\n12\n13   stipulate as follows in support of their request for consolidation of the above-captioned actions\n\n14   (the \u201cRelated Actions\u201d), appointment as Co-Lead Plaintiffs, and approval of their selection of Co-\n15   Lead Counsel:\n16\n            WHEREAS, the Related Actions have been filed against Iovance Biotherapeutics, Inc.\n17\n     and certain of its current and former executives and directors, alleging fraud claims under the\n18\n19   Securities Exchange Act of 1934;\n\n20          WHEREAS, Federal Rule of Civil Procedure 42(a) provides that a court may order all\n\n21   actions consolidated if they involve \u201ccommon issues of law or fact.\u201d;\n22\n            WHEREAS, the Related Actions involve common legal and factual issues, such that\n23\n     efficiency and consistency will result from their consolidation;\n24\n            WHEREAS, pursuant to the Private Securities Litigation Reform Act of 1995 (\u201cPSLRA\u201d),\n25\n26   15 U.S.C. \u00a7 78u-4(a)(3)(A)(i), on May 16, 2025, after the filing of Sundaram v. Iovance\n\n27   Biotherapeutics, Inc., 5:25-cv-04177-EKL \u2013 the first of the Related Actions to be filed \u2013 a notice\n28\n                                                     2\n        STIPULATION AND [PROPOSED] ORDER CONSOLIDATING RELATED ACTIONS, APPOINTING\n       CO-LEAD PLAINTIFFS, AND APPROVING SELECTION OF CO-LEAD COUNSEL \u2013 Case No. 5:25-cv-\n                                          04177-EKL\n\f     Case 5:25-cv-04177-EKL          Document 88         Filed 09/19/25    Page 3 of 10\n\n\n\n\n     was published over a national wire service, duly advising putative class members of the action\n 1\n 2   informing them of their right to seek appointment as lead plaintiff within 60 days;\n\n 3          WHEREAS, on July 14, 2025, ten movants or movant groups filed timely, separate\n 4   motions seeking consolidation of the Related Actions, appointment as Lead Plaintiff, and\n 5\n     approval of their respective selections of Lead Counsel pursuant to the PSLRA: (i) Gary\n 6\n     LoPiccolo (\u201cLoPiccolo\u201d) (Dkt. No. 18); (ii) Thor Brevik and Elliot Resnick (collectively, \u201cBrevik\n 7\n 8   and Resnick\u201d) (Dkt. No. 28); (iii) Lee Schweizer, Michael A. Macchione, Ann Marie Macchione,\n\n 9   Bradford J. Tierney, and Christopher J. Amoruso (collectively, the \u201cIova Investor Group\u201d) (Dkt.\n10   No. 30); (iv) Mark van den Broek (\u201cvan den Broek\u201d) (Dkt. No. 15); (v) Brian Paplaski\n11\n     (\u201cPaplaski\u201d) (Dkt. No. 45); and (vi) Peter Jay Guthy (\u201cGuthy\u201d) (Dkt. No. 21); (vii) the Merrill\n12\n     and Djie Group (Dkt. No. 24); (viii) Dimitry Farberov, JianJun Wei, and Hassan Pourhossein\n13\n14   (collectively, \u201cthe Iovance Investor Group\u201d) (Dkt. No. 35); (ix) Anthony Westfall (Dkt. No. 46);\n\n15   and (x) Mehdi Hasan (\u201cHasan\u201d) (Dkt. No. 39);\n\n16          WHEREAS, after filing their motions, movants LoPiccolo, Brevik and Resnick, the Iova\n17\n     Investor Group, van den Broek, Paplaski, Guthy, and Hasan subsequently filed either statements\n18\n     of non-opposition or notices of withdrawal of their respective motions (see Dkt. Nos. 55, 57, 63,\n19\n     64-66, 71);\n20\n21          WHEREAS, after the foregoing withdrawals and statements of non-opposition, only the\n\n22   Merrill and Djie Group, Westfall, and the Iovance Investor Group continued to pursue their\n23\n     respective lead plaintiff motions;\n24\n            WHEREAS, the PSLRA provides, inter alia, that the most adequate plaintiff to serve as\n25\n     Lead Plaintiff is, in the determination of the Court, the \u201cperson or group of persons\u201d that has the\n26\n27   largest financial interest in the relief sought by the class and otherwise satisfies the relevant\n\n28\n                                                     3\n        STIPULATION AND [PROPOSED] ORDER CONSOLIDATING RELATED ACTIONS, APPOINTING\n       CO-LEAD PLAINTIFFS, AND APPROVING SELECTION OF CO-LEAD COUNSEL \u2013 Case No. 5:25-cv-\n                                          04177-EKL\n\f     Case 5:25-cv-04177-EKL            Document 88        Filed 09/19/25    Page 4 of 10\n\n\n\n\n     requirements of Rule 23 of the Federal Rules of Civil Procedure (\u201cRule 23\u201d) (15 U.S.C. \u00a7 78u-\n 1\n 2   4(a)(3)(B)(iii));\n\n 3           WHEREAS, the PSLRA provides that, subject to the approval of the Court, the most\n 4   adequate plaintiff will select and retain counsel to represent the class (15 U.S.C. \u00a7 78u-\n 5\n     4(a)(3)(B)(v));\n 6\n             WHEREAS, the Merrill & Djie Group and Westfall have each provided sworn\n 7\n 8   Certifications pursuant to the PSLRA in support of their respective applications for Lead Plaintiff\n\n 9   appointment, setting forth, inter alia, their transactions in Iovance securities (see Dkt. No. 24 at\n10   9; Dkt. Nos. 25-2, 25-3);\n11\n             WHEREAS, the Merrill & Djie Group and Westfall each having alleged significant losses\n12\n     in connection with the fraud alleged in the Related Actions, both have significant financial\n13\n14   interests in the outcome of this litigation;\n\n15           WHEREAS, the Merrill & Djie Group and Westfall are also each qualified to serve as co-\n\n16   lead plaintiffs in this case given, among other things, their interest in aggressively pursuing the\n17\n     claims in the Related Actions and their willingness to discharge the obligations of class\n18\n     representatives in the Related Actions as described in the memoranda of points and authorities\n19\n     submitted in support of the Merrill & Djie Group and Westfall\u2019s respective motions (see Dkt. No.\n20\n21   24 at 9; Dkt. Nos. 46 at 9-10);\n\n22           WHEREAS, having reviewed one another\u2019s submissions to the Court, the Merrill & Djie\n23\n     Group and Westfall believe that they each satisfy the typicality and adequacy requirements of\n24\n     Rule 23;\n25\n26\n27\n28\n                                                      4\n        STIPULATION AND [PROPOSED] ORDER CONSOLIDATING RELATED ACTIONS, APPOINTING\n       CO-LEAD PLAINTIFFS, AND APPROVING SELECTION OF CO-LEAD COUNSEL \u2013 Case No. 5:25-cv-\n                                          04177-EKL\n\f     Case 5:25-cv-04177-EKL          Document 88          Filed 09/19/25     Page 5 of 10\n\n\n\n\n             WHEREAS, the Merrill & Djie Group and Westfall believe that, rather than continue to\n 1\n 2   litigate their competing motions, it is in the best interest of the Class to amicably resolve the\n\n 3   motions and pool their resources to effectively and efficiently prosecute the Related Actions;\n 4           WHEREAS, having reviewed one another\u2019s submissions to the Court, the Merrill & Djie\n 5\n     Group and Westfall believe that it is in the best interests of the Class for the Merrill & Djie Group\n 6\n     and Westfall to serve as Co-Lead Plaintiffs and for their respective selections of The Rosen Law\n 7\n 8   Firm, P.A. (\u201cRosen Law\u201d) and Pomerantz LLP (\u201cPomerantz\u201d) to serve as Co-Lead Counsel;\n\n 9           WHEREAS, the Merrill & Djie Group and Westfall are committed to supervising the\n10   conduct of this litigation by their counsel and to ensuring that counsel coordinate appropriately,\n11\n     prosecute the Related Actions efficiently, and avoid any duplication of effort in the conduct of\n12\n     the litigation;\n13\n14           WHEREAS, courts have endorsed stipulations among competing Lead Plaintiff movants,\n\n15   like here, as promoting the statutory purposes of the PSLRA, and have permitted \u201cindependent\n\n16   lead plaintiff movants [to] join together to help ensure that adequate resources and experience are\n17\n     available to the prospective class in the prosecution of th[e] action and because [e]mploying a co-\n18\n     lead plaintiff structure . . . will also provide the proposed class with the substantial benefits of\n19\n     joint decision-making.\u201d In re Rockwell Med., Inc. Sec. Litig., No. 1:16-cv-01691-RJS, Dkt. No.\n20\n21   18 at 2-3 (S.D.N.Y. May 20, 2016) (internal quotation marks omitted) (citing Pirelli Armstrong\n\n22   Tire Corp. Retiree Med. Benefits Tr. v. LaBranche & Co., 229 F.R.D. 395, 420 (S.D.N.Y. 2004));\n23\n     see also Ortiz v. Canopy Growth Corporation et al, No. 2:19-cv-20543 (D.N.J.) (\u201cOrtiz\u201d), Dkt.\n24\n     No. 27 (approving stipulation of competing lead plaintiff movants to serve as co-lead plaintiffs\n25\n     and approving their selection of co-lead counsel); Deputy v. Akebia Therapeutics, Inc. et al., No.\n26\n27   1:22-cv-01411-AMD-VMS (E.D.N.Y.), ECF Order on June 28, 2022 (same); In re Grab\n\n28\n                                                      5\n        STIPULATION AND [PROPOSED] ORDER CONSOLIDATING RELATED ACTIONS, APPOINTING\n       CO-LEAD PLAINTIFFS, AND APPROVING SELECTION OF CO-LEAD COUNSEL \u2013 Case No. 5:25-cv-\n                                          04177-EKL\n\f     Case 5:25-cv-04177-EKL           Document 88         Filed 09/19/25    Page 6 of 10\n\n\n\n\n     Holdings Ltd. Sec. Litig., No. 1:22-cv-02189-VM (S.D.N.Y.), Dkt. No. 39 (same); In re\n 1\n 2   Altimmune, Inc. Sec. Litig., No. 8:24-cv-01315-ABA (D. Md.), Dkt. No. 22 (same); Pizzuto v.\n\n 3   Homology Meds., Inc., No. 2:22-cv-01968-FLA-JPR (C.D. Cal.), Dkt. No. 38 (same); Maurer v.\n 4   Argos Therapeutics Inc., et al., No. 1:17-cv-00216-TDS-LPA (M.D.N.C.), Dkt. No. 26 (same);\n 5\n     In re Facebook, Inc. Sec. Litig., No. 5:18-cv-01725-EJD, Dkt. No. 56 at 2-3 (N.D. Cal. Aug. 3,\n 6\n     2018) (approving stipulation of lead plaintiff movants where movants \u201cconcluded that a\n 7\n 8   protracted dispute concerning lead plaintiff appointment . . . [was] not in the best interests of the\n\n 9   class and that jointly prosecuting [the] litigation would be appropriate and assist with the speedy\n10   commencement of [the] litigation\u201d); see also In re Millennial Media, Inc. Sec. Litig., 87 F. Supp.\n11\n     3d 563, 570 (S.D.N.Y. 2015) (\u201cA co-lead plaintiff structure best protects the interests of the class\n12\n     . . . and gives the class the advantages of the combined knowledge, experience, and judgment of\n13\n14   both lead plaintiffs.\u201d (collecting cases));\n\n15           WHEREAS, Rosen Law and Pomerantz have successfully prosecuted similar securities\n\n16   class actions under the PSLRA as Co-Lead Counsel, including in this District. See, e.g., Chan, et\n17\n     al., v. New Oriental Education & Technology Group Inc., et al., No. 2:16-cv-09279-KSH-CLW\n18\n     (D.N.J.); Ortiz; Vataj v. Johnson, et al., No. 4:19-cv-06996-HSG (N.D. Cal.); In re Blue Apron\n19\n     Holdings, Inc. Securities Litigation, No. 17-cv-04846-NGG-PK (E.D.N.Y.); Pirnik v. Fiat\n20\n21   Chrysler Automobiles N.V. et al., No. 1:15-cv-07199-JMF (S.D.N.Y.); Whiteley, et al. v. Zynerba\n\n22   Pharmaceuticals, Inc., et al., No. 2:19-cv-04959-NIQA (E.D. Pa.); Thomas, et al., v. MagnaChip\n23\n     Semiconductor Corp., et al., No. 3:14-CV-01160-JST (N.D. Cal.); Thorpe, et al., v. Walter\n24\n     Investment Management Corp., No. 1:14-cv-20880-UU (S.D. Fla.); and\n25\n26\n27\n28\n                                                      6\n        STIPULATION AND [PROPOSED] ORDER CONSOLIDATING RELATED ACTIONS, APPOINTING\n       CO-LEAD PLAINTIFFS, AND APPROVING SELECTION OF CO-LEAD COUNSEL \u2013 Case No. 5:25-cv-\n                                          04177-EKL\n\f     Case 5:25-cv-04177-EKL          Document 88          Filed 09/19/25      Page 7 of 10\n\n\n\n\n            WHEREAS, the Iovance Investor Group has agreed to not oppose the collective\n 1\n 2   appointment of the Merrill & Djie Group and Westfall and has agreed that it, or certain of its\n\n 3   members, will serve as additional plaintiffs if the co-lead plaintiffs deem it appropriate;\n 4          IT IS HEREBY STIPULATED AND AGREED THAT, subject to the Court\u2019s approval,\n 5\n     as follows:\n 6\n            1.      The Related Actions are hereby consolidated for all purposes pursuant to Rule\n 7\n 8   42(a) of the Federal Rules of Civil Procedure;\n\n 9          2.      These actions shall be referred to herein as the \u201cConsolidated Action.\u201d This Order\n10   shall apply to the Consolidated Action and to each case that is subsequently filed in this Court\n11\n     that relates to the same subject matter as in the Consolidated Action;\n12\n            3.      Every pleading in this Consolidated Action shall bear the following Caption:\n13\n14    IN RE IOVANCE SECURITIES LITIGATION                   Case No. 5:25-cv-04177-EKL\n15    THIS DOCUMENT RELATES TO:\n16                                                          CLASS ACTION\n17\n18                                                          [TITLE OF DOCUMENT]\n19\n20          4.      When the document being filed pertains to all actions, the phrase \u201cAll Actions\u201d\n21   shall appear immediately after the phrase \u201cThis Document Relates To:\u201d. When the document\n22\n     applies to some, but not all, of the actions, the document shall list, immediately after the phrase\n23\n     \u201cThis Document Relates To:\u201d, the docket number for each individual action to which the\n24\n25   document applies, along with the name of the first-listed plaintiff in said action;\n\n26          5.      The Merrill & Djie Group\u2019s and (Dkt. No. 24) and Westfall\u2019s (Dkt. No. 46)\n\n27   motions are granted and are hereby appointed Co-Lead Plaintiffs in the Consolidated Action and\n28\n                                                      7\n        STIPULATION AND [PROPOSED] ORDER CONSOLIDATING RELATED ACTIONS, APPOINTING\n       CO-LEAD PLAINTIFFS, AND APPROVING SELECTION OF CO-LEAD COUNSEL \u2013 Case No. 5:25-cv-\n                                          04177-EKL\n\f     Case 5:25-cv-04177-EKL         Document 88         Filed 09/19/25    Page 8 of 10\n\n\n\n\n     any subsequently filed or transferred actions that are consolidated with the Consolidated Action,\n 1\n 2   pursuant to 15 U.S.C. \u00a7 78u-4(a)(3)(B);\n\n 3          6.      Co-Lead Plaintiffs\u2019 selections of Rosen Law and Pomerantz as Co-Lead Counsel\n 4   are hereby approved.\n 5\n 6\n     Dated: September 19, 2025            Respectfully submitted,\n 7\n 8                                        THE ROSEN LAW FIRM, P.A.\n\n 9                                        /s/Laurence M. Rosen\n                                          Laurence M. Rosen, Esq. (SBN 219683)\n10                                        355 South Grand Avenue, Suite 2450\n11                                        Los Angeles, CA 90071\n                                          Telephone: (213) 785-2610\n12                                        Facsimile: (213) 226-4684\n                                          Email: lrosen@rosenlegal.com\n13\n14                                         Counsel for Lindy Merrill and Tony Djie and [Proposed]\n                                           Co-Lead Counsel for Plaintiffs and the Class\n15\n                                          THE SCHALL LAW FIRM\n16                                        Brian Schall (290685)\n                                          2049 Century Park East, Suite 2460\n17\n                                          Los Angeles, CA 90067\n18                                        Telephone: (310) 301-3335\n                                          brian@schallfirm.com\n19\n                                          Additional Counsel for Lindy Merrill and Tony Djie\n20\n21                                        POMERANTZ LLP\n\n22                                        /s/ Jennifer Pafiti\n                                          Jennifer Pafiti (SBN 282790)\n23\n                                          1100 Glendon Avenue, 15th Floor\n24                                        Los Angeles, California 90024\n                                          Telephone: (310) 405-7190\n25                                        jpafiti@pomlaw.com\n26\n                                          POMERANTZ LLP\n27                                        Jeremy A. Lieberman\n                                          (pro hac vice application forthcoming)\n28\n                                                    8\n        STIPULATION AND [PROPOSED] ORDER CONSOLIDATING RELATED ACTIONS, APPOINTING\n       CO-LEAD PLAINTIFFS, AND APPROVING SELECTION OF CO-LEAD COUNSEL \u2013 Case No. 5:25-cv-\n                                          04177-EKL\n\f     Case 5:25-cv-04177-EKL     Document 88        Filed 09/19/25   Page 9 of 10\n\n\n\n\n                                      J. Alexander Hood II\n 1                                    (pro hac vice application forthcoming)\n 2                                    600 Third Avenue, 20th Floor\n                                      New York, New York 10016\n 3                                    Telephone: (212) 661-1100\n                                      Facsimile: (917) 463-1044\n 4                                    jalieberman@pomlaw.com\n 5                                    ahood@pomlaw.com\n                                      Counsel for Anthony Westfall and Proposed Co-Lead\n 6                                    Counsel for the Class\n 7                                    GLANCY PRONGAY & MURRAY LLP\n 8\n                                      By: /s/ Charles H. Linehan\n 9                                    Robert V. Prongay\n                                      Charles H. Linehan\n10                                    Pavithra Rajesh\n11                                    1925 Century Park East, Suite 2100\n                                      Los Angeles, California 90067\n12                                    Telephone: (310) 201-9150\n                                      Facsimile: (310) 201-9160\n13                                    Email: clinehan@glancylaw.com\n14\n                                      Counsel for Lead Plaintiff Movants Dimitry Farberov,\n15                                    JianJun Wei, and Hassan Pourhossein (the Iovance\n                                      Investor Group)\n16\n                                      THE LAW OFFICES OF FRANK R. CRUZ\n17\n                                      Frank R. Cruz\n18                                    1999 Avenue of the Stars, Suite 1100\n                                      Los Angeles, CA 90067\n19                                    Telephone: (310) 914-5007\n20\n                                      Additional Counsel for the Iovance Investor Group\n21\n22\n23\n24\n25\n26\n27\n28\n                                               9\n        STIPULATION AND [PROPOSED] ORDER CONSOLIDATING RELATED ACTIONS, APPOINTING\n       CO-LEAD PLAINTIFFS, AND APPROVING SELECTION OF CO-LEAD COUNSEL \u2013 Case No. 5:25-cv-\n                                          04177-EKL\n\f     Case 5:25-cv-04177-EKL    Document 88      Filed 09/19/25   Page 10 of 10\n\n\n\n\n 1 PURSUANT TO STIPULATION, IT IS SO ORDERED.\n 2\n 3   DATED: ______________, 2025                 ____________________________________\n                                                 THE HONORABLE EUMI K. LEE\n 4                                               UNITED STATES DISTRICT JUDGE\n 5\n 6\n 7\n 8\n 9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n                                              10\n        STIPULATION AND [PROPOSED] ORDER CONSOLIDATING RELATED ACTIONS, APPOINTING\n       CO-LEAD PLAINTIFFS, AND APPROVING SELECTION OF CO-LEAD COUNSEL \u2013 Case No. 5:25-cv-\n                                          04177-EKL\n\f","ocr_status":2,"date_upload":"2025-11-12T15:31:29.954308-08:00","document_number":"88","attachment_number":null,"pacer_doc_id":"035026218155","is_available":true,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"Stipulation and Proposed Order","acms_document_guid":""}],"date_created":"2025-09-19T09:39:48.712257-07:00","date_modified":"2026-01-27T00:03:51.121090-08:00","date_filed":"2025-09-19","time_filed":"09:05:43","entry_number":88,"recap_sequence_number":"2025-09-19.001","pacer_sequence_number":357,"description":"STIPULATION WITH PROPOSED ORDER Consolidating Related Actions, Appointing Co-Lead Plaintiffs, and Approving selection of Co-lead Counsel filed by Lindy Merrill, Tony Djie. (Rosen, Laurence) (Filed on 9/19/2025) Modified on 9/24/2025 (kmg, COURT STAFF). (Entered: 09/19/2025)","tags":[]},{"resource_uri":"https://www.courtlistener.com/api/rest/v4/docket-entries/435165059/","id":435165059,"docket":"https://www.courtlistener.com/api/rest/v4/dockets/70274365/","recap_documents":[{"resource_uri":"https://www.courtlistener.com/api/rest/v4/recap-documents/449572498/","id":449572498,"tags":[],"absolute_url":"/docket/70274365/338/in-re-iovance-biotherapeutics-inc-securities-litigation/","date_created":"2025-08-19T11:40:41.829535-07:00","date_modified":"2025-08-19T11:40:41.853005-07:00","sha1":"","page_count":null,"file_size":null,"filepath_local":null,"filepath_ia":"","ia_upload_failure_count":null,"thumbnail":null,"thumbnail_status":0,"plain_text":"","ocr_status":null,"date_upload":null,"document_number":"338","attachment_number":null,"pacer_doc_id":"035025020821","is_available":false,"is_free_on_pacer":null,"is_sealed":null,"document_type":1,"description":"","acms_document_guid":""}],"date_created":"2025-08-19T11:40:41.774800-07:00","date_modified":"2025-08-19T11:40:41.791270-07:00","date_filed":"2024-10-28","time_filed":null,"entry_number":338,"recap_sequence_number":"2024-10-28.001","pacer_sequence_number":1023,"description":"Post-Distribution Accounting Form . (Campisi, Jeffrey) (Filed on 10/28/2024) (Entered: 10/28/2024)","tags":[]}],"entries_total":"https://www.courtlistener.com/api/rest/v4/docket-entries/?count=on&docket=70274365&page_size=40"}